(Click sector to view stock chart)
(Click stock symbol to view stock chart, Support, Resistance, Pivot, Option chain, Volume, P/E, High, Low, Close, Market Cap, Average Volume, Dividend, % Change, $ Change, R1, R2, S1, S2, Previous Close, RSI - MACD - Williams %R - Stochastics - PPO, CMF, ADX, Aroon and more.......)
Illumina, Inc. engages in the development and marketing of tools for the large-scale analysis of genetic variation and function. Its tools provide information used to improve drugs and therapies, customize diagnoses and treatment, and cure diseases. Its genotyping service product line combines the company's BeadArray technology with an automated, laboratory information management system controlled process to provide throughput identification of the common form of genetic variation, known as single nucleotide polymorphisms. The BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously. This technology includes the BeadArray Reader, GoldenGate assay protocols, laboratory information management system and analytical software, fluid-handling robotics, and access to Sentrix arrays and reagent kits for analyzing genetic sequences. Illumina offers Oligator technology for the parallel synthesis of various oligonucleotides for genomics applications. The company also provides DASL, a gene expression assay, for generating gene expression profiles from RNA samples, including those containing partially degraded RNAs. It offers SNP Genotyping, gene expression profiling, scanning instrumentation, and high-throughput synthesis. Illumina has a strategic collaboration with Invitrogen Corporation to synthesize and distribute oligos. The company markets and distributes its products to pharmaceutical, biotechnology, agrichemical, diagnostics, and consumer products companies, as well as to academic or private research centers in North America, Europe, Japan, Singapore, and the Pacific Rim countries. Illumina was founded by John R. Stuelpnagel and Mark Chee in 1998. The company is based in San Diego, California.
SAVIENT PHARMACEUTICALS INC (SVNT)
No description available.
INDEVUS PHARMACEUTICALS INC (IDEV)
Indevus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the acquisition, development, and commercialization of products in the fields of urology, gynecology, and infectious diseases. The company markets its product, SANCTURA for the treatment of overactive bladder and has various compounds in clinical development, including SANCTURA XR under phase III program, a once-a-daily formulation of SANCTURA; NEBIDO, which is under phase III trial is used for the treatment of male hypogonadism; PRO 2000, which is under phase I/II clinical trial is used for the prevention of infection by HIV and other sexually transmitted pathogens; IP 751, which is under phase II trial is used for interstitial cystitis; Pagoclone, which is under phase II trial is used for stuttering; and Aminocandin, which is under phase I trial is used for systemic fungal infections. It focuses on the clinical development, regulatory review, and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, Massachusetts.
QUESTCOR PHARMACEUTICALS INC (QSC)
Questcor Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of novel therapeutics for the treatment of neurological disorders with a focus on central nerves system. The company's primary product is H.P. Acthar Gel, a natural source of adrenocorticotropic hormone (ACTH), which provides prolonged release after intramuscular or subcutaneous injection. H.P. Acthar Gel is indicated for the treatment of acute exacerbations of multiple sclerosis, as well as for various other conditions. The company is in the process of building a development pipeline of additional prescription-only therapeutics, with primary focus on the field of neurology. Questcor is headquartered in Union City, California.
BIOMARIN PHARMACEUTICAL INC (BMRN)
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of biopharmaceuticals and therapeutics for serious diseases and medical conditions. Its product portfolio comprises three approved products and various investigational product candidates. The company offers Aldurazyme, an enzyme replacement therapy for the treatment of mucopolysaccharidosis I, a progressive and debilitating life-threatening genetic disease that frequently results in death during childhood or early adulthood; Naglazyme, an enzyme replacement therapy for the treatment of mucopolysaccharidosis VI, an inherited, life-threatening lysosomal storage disorder; and Orapred, a drug primarily used to treat asthma exacerbations in children and other inflammatory conditions. BioMarin is also developing additional proprietary formulations of Orapred, including Orapred ODT (orally disintegrating tablets), which is under U.S. FDA review. In addition, the company is developing various other product candidates, including Phenoptin, a proprietary synthetic oral form of tetrahydrobiopterin for the treatment of moderate to mild forms of phenylketonuria (PKU); Phenylase, a preclinical-stage enzyme substitution therapy for the treatment of the more severe form of PKU; and 6R-BH4 for vascular dysfunction. BioMarin has a joint venture, BioMarin/Genzyme LLC, with Genzyme Corporation for the development and commercialization of Aldurazyme, as well as a strategic business partnership with Daiichi Suntory Pharma Co., Ltd. and Serono for Phenoptin, Phenylase and 6R-BH4 for cardiovascular indications. The company was founded in 1996 and is headquartered in Novato, California.
POLYDEX PHARMACEUTICALS LIMITED (POLXF)
Polydex Pharmaceuticals Limited, through its subsidiaries, engages in the research, development, manufacture, and marketing of biotechnology-based products for the human pharmaceutical market. It offers Dextran and derivative products, including Iron Dextran, a derivative of Dextran, which is injected into pigs at birth as a treatment for anemia; and Dextran Sulphate, a chemical derivative of Dextran used in research applications by the pharmaceutical industry and other centers of chemical research. The company also manufactures sterile injectable products, tablets and boluses, internal and external solutions, ointments, and powders for the worldwide veterinary pharmaceutical industry. In addition, it is also developing Ushercell, a human pharmaceutical compound for topical vaginal use primarily in the prevention of transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies. The company sells its Iron Dextran primarily in Europe, the United States, and Canada; and Dextran Sulphate in Australia, France, the Netherlands, New Zealand, and the United States through independent distributors and wholesalers. It has strategic alliance with CONRAD for the development of cellulose sulphate products. The company was incorporated in 1966 and is based in Toronto, Canada.
ASPREVA PHARMACEUTICALS CORPORATION (ASPV)
Aspreva Pharmaceuticals Corporation, a development stage company, engages in the identification, development, and commercialization of indications for approved drugs and drug candidates. The company, through its collaboration agreement with Hoffmann-La Roche, Inc. and F. Hoffmann-La Roche, Ltd. develops, markets and promotes CellCept', which is used for various autoimmune disease applications, including lupus nephritis, myasthenia gravis, and pemphigus vulgaris. It sells its product primarily in the United States, Canada, and European Union. Aspreva Pharmaceuticals was founded by Michael R. Hayden, Richard M. Glickman, and Noel F. Hall. The company was incorporated in 2001 and is headquartered in Victoria, Canada.
REGENERON PHARMACEUTICALS INC (REGN)
Regeneron Pharmaceuticals, Inc. engages in the discovery and development of pharmaceutical products for the treatment of human disorders and conditions. Its clinical and preclinical pipeline includes product candidates for the treatment of cancer, diseases of the eye, rheumatoid arthritis, and other inflammatory conditions like allergies, asthma, and other diseases and disorders. The company primarily focuses on the development of the VEGF Trap in oncology and eye diseases, which are in phase I clinical trails; and the IL (Interleukin)-1 Trap in various indications in, which interleukin-1 plays a role, including rheumatoid arthritis and other inflammatory conditions. VEGF TRAP is a protein-based product candidate designed to bind Vascular Endothelial Growth Factor (VEGF) and the related Placental Growth Factor, and prevent their interaction with cell surface receptors. Interleukin-1 Trap, which is in preclinical stage, is a protein-based product candidate designed to bind the interleukin-1 cytokine and prevent its interaction with cell surface receptors used for the treatment of diseases associated with inflammation in blood vessels. IL-1 Trap is in phase 2b study for its use in rheumatoid arthritis in a double blind, placebo-controlled, and multicenter trial. Regeneron's product candidates in preclinical development stage include Interleukin-4/Interleukin-13 Trap, a protein-based product candidate designed to bind both the interleukin-4 and interleukin-13, which is used for the treatment of diseases, such as asthma, allergic disorders, and other inflammatory diseases. The company also provides contract manufacturing services for the production of an intermediate for a pediatric vaccine. Regeneron has collaboration and licensing agreements with sanofi-aventis Group, Novartis Pharma AG, and The Procter & Gamble Company. The company was founded by Leonard S. Schleifer in 1988. Regeneron is headquartered in Tarrytown, New York.
CytRx Corporation, a biopharmaceutical company, engages in the development and commercialization of human therapeutics primarily in the area of small molecules and ribonucleic acid interference (RNAi). It owns 3 clinical-stage compounds based on its small molecule molecular chaperone' co-induction technology, as well as a targeted library of 500 small molecule drug candidates that would be used to screen for new drug candidates. The company initiated a Phase II clinical trial with its lead small molecule product candidate, Arimoclomol for the treatment for amyotrophic lateral sclerosis (ALS). Arimoclomol received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration. CytRx has also licensed from the University of Massachusetts Medical School (UMMS) the exclusive worldwide commercial rights to a novel DNA-based HIV vaccine technology, which demonstrated positive interim Phase I clinical trial results indicating its ability to produce potent antibody responses with neutralizing activity against multiple HIV viral strains. The company has a strategic alliance with UMMS to develop compounds in the areas of ALS, obesity, type II diabetes, and cytomegalovirus using RNAi technology, as well as a research program with Massachusetts General Hospital, Harvard University's teaching hospital, to use RNAi technology to develop a drug for the treatment of ALS. CytRx was incorporated in 1985 and is headquartered in Los Angeles, California.
CELGENE CORPORATION (CELG)
Celgene Corporation engages in the discovery, development, and commercialization of therapies designed to treat cancer and immunological diseases through regulation of cellular, genomic, and proteomic targets. Its lead product, THALOMID, is used for the treatment of acute cutaneous manifestations of moderate to severe erythema nodosum leprosum, and as maintenance therapy to prevent and suppress cutaneous manifestation recurrences. The company, through a supply and distribution agreement, with GlaxoSmithKline, distributes ALKERAN, a therapy for the palliative treatment of multiple myeloma and for palliation of carcinoma of the ovary. Its RITALIN family of drugs includes Focalin (d-MPH), which is used for the treatment of attention deficit disorder and attention deficit hyperactivity disorder in school-age children. The company has various products in the preclinical and clinical-stage, including immunomodulatory drugs and selective cytokine inhibitory drugs. Celgene also produces compounds such as Benzopyrans and Selective Estrogen Receptor Modulators, Kinases Inhibitors, Tubulin Inhibitors, and Ligase Modulators. The company has collaborative agreements with Novartis Pharma AG; and strategic partnership agreements with Pharmion Corporation, Penn Pharmaceuticals Services Limited, and GlaxoSmithKline. The company markets and sells its products in the United States and Canada primarily through wholesale distributors. Celgene was organized in 1980 as a unit of Celanese Corporation and was spun-off in 1986. The company is headquartered in Warren, New Jersey.
LIFECELL CORPORATION (LIFC)
LifeCell Corporation engages in the development and marketing of human-derived tissue-based products for use in reconstructive, urogynecologic, and orthopedic surgical procedures to repair soft tissue defects. It develops regenerative human tissue matrix, a three-dimensional structure that contains vascular channels, proteins, and growth factor binding sites, which provide a template for the regeneration of normal human tissue. The company offers AlloDerm for plastic reconstructive, general surgical, burn, and periodontal procedures; Repliform for urogynecologic surgical procedures; GraftJacket and GraftJacket Xpress for orthopedic applications and lower extremity wounds; AlloCraft DBM for bone grafting procedures; and Cymetra, a particulate form of AlloDerm suitable for injection. It also distributes cryopreserved allograft skin for use as a temporary wound dressing in the treatment of burns. The company has strategic sales and marketing partnership with Boston Scientific Corporation for Repliform; Wright Medical Group, Inc. for GraftJacket and GraftJacket Xpress; Stryker Corporation for AlloCraftDBM; and BioHorizons Implant Systems, Inc. for periodontal applications of AlloDerm. LifeCell was formed in 1986 and is based in Branchburg, New Jersey.
Heska Corporation engages in the discovery, development, manufacture, marketing, sale, and distribution of veterinary products. The company operates in two segments, Core Companion Animal Health (CCA); and Other Vaccines, Pharmaceuticals, and Products (OVP). The CCA segment offers diagnostic and monitoring instruments and supplies; single use diagnostic and other tests; vaccines; and pharmaceuticals, primarily for canine and feline use. This segment primarily provides various products, including handheld electrolyte instrument, chemistry instrument, and hematology instrument and their consumables. The OVP segment offers private label vaccine and pharmaceuticals, primarily for cattle, as well as for other animals, including small mammals, horses, and fish. The company sells its products directly, as well as through independent third party distributors and other distribution relationships. The company was incorporated as Paravax, Inc. in 1988 and changed its name to Heska Corporation in 1995. Heska is headquartered in Loveland, Colorado.
MANNKIND CORPORATION (MNKD)
MannKind Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for diseases, such as diabetes and cancer. It commenced phase three clinical trials in Europe of its lead product, the Technosphere insulin system, to treat diabetes. This therapy consists of a dry powder Technosphere formulation of insulin that is inhaled into the deep lung using MedTone inhaler. Its technology is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. The company was incorporated in 1991 as Pharmaceutical Discovery Corporation and changed its name to MannKind Corporation in 2001. MannKind Corporation is headquartered in Valencia, California.
Novavax, Inc. engages in the research, development, and commercialization of products for women's health and infectious diseases. Its primary product candidate ESTRASORB, a topical emulsion for estrogen therapy, is used for the treatment of vasomotor symptoms associated with menopause. The company's other products comprise a line of prenatal multivitamin tablets, including Novanatal, NovaStart, and Nestabs for use before, during, and after pregnancy; Gynodiol, an oral estrogen replacement therapy; AVC Cream for the treatment of vaginal infection; and Analpram HC for relief of inflammation and pruritus associated with conditions, such as hemorrhoids and anal fissures. Novavax is also developing ANDROSORB, a topical lotion for testosterone replacement therapy in women; ANDRO-Ject, which delivers therapeutic levels of androgen using a subcutaneous testosterone delivery system; and delivery systems, and therapeutic and preventative vaccines for various markets. In addition, the company conducts research and development on preventative vaccines and proteins for infectious diseases and cancers; and tolerogens to prevent the initiation and progression of stroke, heart attack, and other inflammatory diseases. Novavax has collaborative agreements with the National Institutes of Health for the development of AIDS vaccine and an avian flu vaccine to prevent a pandemic outbreak; National Cancer Institute to develop anticancer vaccines for the treatment of melanoma; NIAID, Walter Reed Army Institute for Research, and GlaxoSmithKline Pharmaceuticals for the development of vaccines to prevent hepatitis caused by Hepatitis E virus; and with Wave Biotech LLC to develop pandemic influenza vaccine production technologies. The company sells its products to obstetricians, gynecologists, managed care organizations, wholesalers, and retail pharmacies through direct sales force and distributors in the United States. Novavax was formed in 1987 and is headquartered in Malvern, Pennsylvania.
THIRD WAVE TECHNOLOGIES INC (TWTI)
Third Wave Technologies, Inc. operates as a molecular diagnostics company in the United States. It engages in the development and marketing of molecular diagnostic solutions for various deoxyribonucleic acid and ribonucleic acid analysis applications, providing clinicians and researchers with molecular solutions. Its products include analyte specific reagents that allow laboratories to create assays to perform hepatitis C virus genotyping, to screen for cystic fibrosis and other inherited disorders, and to test for the Factor V Leiden, and a host of other mutations associated with predisposition to cardiovascular and other diseases. The company's products provide clinicians and researchers with solutions for diagnosis and treatment of disease. The company's molecular diagnostic products are used by clinical testing laboratories that perform prognostic, diagnostic, and monitoring testing. Third Wave Technologies was founded by Lance Fors in 1993. The company is headquartered in Madison, Wisconsin.
Nuvelo, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of acute cardiovascular indications and cancer. Its product candidates include alfimeprase, ARC183, and recombinant nematode anticoagulant protein c2 (rNAPc2). Alfimeprase, a blood clot dissolver is in Phase III clinical trials. rNAPc2 is in phase IIA placebo controlled clinical trial for use in treating acute coronary syndromes, including unstable angina and non-ST segment elevation myocardial infarction. ARC183 is a thrombin inhibitor for potential use in coronary artery bypass graft surgery, percutaneous coronary intervention, and other acute anticoagulant applications. The company has collaboration and licensing agreements with Amgen, Inc.; Dendreon Corporation; Kirin Brewery Co., Ltd.; Bayer HealthCare AG; and Archemix Corporation. The company was founded in 1991. It was formerly known as Hyseq Pharmaceuticals, Inc. and changed its name to Nuvelo, Inc. in 2003. Nuvelo is headquartered in Sunnyvale, California.
GILEAD SCIENCES INC (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for patients suffering from life-threatening diseases primarily in North America, Europe, and Australia. It focuses its research and clinical programs on anti-infectives. The company's products include Viread, Emtriva, and Truvada, which are used for the treatment of human immunodeficiency virus infection in adults; AmBisome, an antifungal agent to treat serious invasive fungal infections caused by various fungal species; Hepsera, which is used for the treatment of chronic hepatitis B infection; Vistide, used for the treatment of cytomegalovirus retinitis; and DaunoXome, a liposomal formulation of the anticancer agent daunorubicin, for the treatment of AIDS-related Kaposi's sarcoma. Its products also comprise Tamiflu, which is used for the prevention and treatment of influenza; and Macugen, for the treatment of neovascular age-related macular degeneration. Gilead sells its products primarily through wholesalers and distributors. The company has collaborative relationships with Bristol-Myers Squibb Company; Achillion Pharmaceuticals, Inc.; EyeTech Pharmaceuticals, Inc.; Fujisawa Healthcare, Inc.; GlaxoSmithKline; Japan Tobacco, Inc.; Pfizer, Inc.; F. Hoffmann-La Roche, Ltd.; and Sumitomo Pharmaceuticals Co., Ltd. Gilead was founded by Michael Riordan in 1987. The company is headquartered in Foster City, California.
NABI BIOPHARMACEUTICALS (NABI)
Nabi Biopharmaceuticals engages in the development and commercialization of products in the areas of Gram-positive bacterial infections, hepatitis, nephrology, and nicotine addiction. The company markets three products: PhosLo for treatment of hyperphosphatemia in end-stage renal failure patients; Nabi-HB for the prevention of hepatitis B infections; and Aloprim for the treatment of chemotherapy-induced hyperuricemia or high uric acid levels. Nabi also has products in various stages of clinical and preclinical development. Its advanced StaphVAX, which is in Phase III clinical development, is designed to prevent the most dangerous and prevalent strains of Staphylococcus aureus bacterial infections. The company's other products in development include Altastaph, an antibody for prevention of Staphylococcus aureus infections; NicVAX, a vaccine to treat nicotine addiction; and Civacir, an antibody for preventing hepatitis C virus reinfection in liver transplant patients. The company also offers contract manufacturing services. Nabi sells its biopharmaceutical products to wholesalers, distributors, hospitals, and home healthcare companies, as well as sells its antibody products to pharmaceutical and diagnostic product manufacturers. The company has strategic alliances with Public Health Services/National Institutes of Health; Chiron Corporation; Pfizer; and Cambrex BioScience of Baltimore, Inc. Nabi is headquartered in Boca Raton, Florida.
AMYLIN PHARMACEUTICALS INC (AMLN)
Amylin Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and cardiovascular disease. Its primary drug candidates include exenatide and SYMLIN, which have completed phase III clinical trials for the treatment of diabetes. The company is developing exenatide for the treatment of type II diabetes, as well as studying a sustained release formulation of exenatide. Amylin Pharmaceuticals is developing SYMLIN for the treatment of patients with type I diabetes and insulin-using patients with type II diabetes. SYMLIN injection received the United States Food and Drug Administration approval for use in conjunction with insulin to treat diabetes. The company also has two early stage development programs for the treatment of obesity, including a phase II program for AC137 and AC162352 that completed a Phase I study. In addition, it is studying AC2592, which is in a phase II program for the treatment of patients with severe congestive heart failure, as well as AC3056, which is in phase I program for the treatment of atherosclerosis-related cardiovascular disease. Amylin Pharmaceuticals has a collaboration agreement with Eli Lilly and Company for the development and commercialization of exenatide, including sustained release formulations of that compound. It also has a collaboration agreement with Alkermes, Inc. for the development, manufacture, and commercialization of an injectable sustained-release formulation of exenatide. The company was co-founded by Howard E. Greene, Jr in 1987. Amylin Pharmaceuticals is headquartered in San Diego, California.
CHELSEA THERAPEUTICS INTERNATIONAL LTD (CHTP)
No description available.
Theravance, Inc. engages in the discovery, development, and commercialization of small molecule medicines for respiratory disease, bacterial infections, overactive bladder, and gastrointestinal disorders. As of April 7, 2005, telavancin, the company's injectable antibiotic, was in Phase 3 clinical studies for the treatment of Gram-positive infections and in patients whose infections were due to methicillin-resistant Staphylococcus aureus in both complicated skin and skin structure infections and hospital-acquired pneumonia. Its other product candidates in development include TD-6301 for overactive bladder; TD-2749 and TD-5108 for gastrointestinal motility dysfunction; and TD-4756 for emergence from hypnosis. Theravance has various other product candidates in the identification and preclinical testing stages. The company has a collaboration agreement with GlaxoSmithKline (GSK) to develop and commercialize long acting beta2 agonist product candidates for the treatment of asthma and chronic obstructive pulmonary disease. It also has a strategic alliance with GSK. Theravance, Inc. has collaboration with Astellas Pharma, Inc. for the development and commercialization of its investigational antibiotic, telavancin. The company was co-founded by P. Roy Vagelos and George M. Whitesides in 1996. It was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in 2002. Theravance is headquartered in South San Francisco, California.
ENZON PHARMACEUTICALS INC (ENZN)
Enzon Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of human therapeutics for life threatening diseases. The company markets four human therapeutic products, such as ABELCET, ONCASPAR, ADAGEN, and DEPOCYT. ABELCET is a lipid complex formulation of amphotericin B used primarily in the hospital to treat immuno-compromised patients with invasive fungal infections. ONCASPAR is a PEG-enhanced version of a naturally occurring enzyme called L-asparaginase. It is approved in the United States, Canada, and Germany; and is used in conjunction with other chemotherapeutics to treat patients with acute lymphoblastic leukemia who are hypersensitive or allergic to native or unmodified forms of L-asparaginase. ADAGEN is used to treat patients afflicted with a type of severe combined immunodeficiency disease, also known as the Bubble Boy' disease, which is caused by the chronic deficiency of the adenosine deaminase enzyme. DEPOCYT is an injectable chemotherapeutic approved for the treatment of patients with lymphomatous meningitis. The company also develops PEG-INTRON, which is used in combination with REBETOL for the treatment of chronic hepatitis C; and ATG FRESENIUS S, a polyclonal antibody preparation that is used for T-lymphocyte suppression in organ transplant patients in order to prevent organ graft rejection. The company has strategic alliances with Nektar Therapeutics, SkyePharma, PLC, and Inex Pharmaceuticals Corporation. Enzon Pharmaceuticals was incorporated in 1981 and is headquartered in Bridgewater, New Jersey.
NASTECH PHARMACEUTICAL COMPANY INC (NSTK)
Nastech Pharmaceutical Company, Inc., a pharmaceutical company, engages in the development and commercialization of products based on proprietary molecular biology-based intranasal drug delivery technology for delivering both small and large molecule drugs. It develops a diverse product portfolio across various therapeutic areas, including products targeted for the treatment of obesity, sexual dysfunction, pain management, and osteoporosis. The company has collaboration agreements with Merck & Co., Inc. for the development of Peptide YY, an obesity product candidate, which is in Phase I clinical trial. In addition, it develops products for osteoporosis; and in collaboration with Par Pharmaceutical, Inc., it develops Parathyroid Hormone (PTH), which is in Phase I clinical trials and calcitonin-salmon intranasal spray. The company was founded in 1983 and is headquartered in Bothell, Washington.
Medicure, Inc., a development stage company, engages in the discovery and development of cardiovascular therapeutics. It primarily develops the MC-1 product, which is used to treat injury from blockages of blood to the heart and the brain, as well as to prevent injury from ischemic reperfusion injury; and MC-4232, a drug that combines the cardio-protective benefit of MC-1 with an ACE Inhibitor, for the treatment of diabetic patients with hypertension and related cardiovascular problems. The company is conducting Phase II human clinical trials for MC-1 and MC-4232. Medicure was founded by Naranjan S. Dhalla and Albert D. Friesen in 1997 and is based in Winnipeg, Canada.
ANIKA THERAPEUTICS INC (ANIK)
Anika Therapeutics, Inc. engages in the development, manufacture, and commercialization of therapeutic products and devices that are designed to repair, protect and heal bone, cartilage, and soft tissue. Its products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. HA enhances joint function and coats, protects, cushions, and lubricates soft tissues. The company's products include ORTHOVISC and HYVISC, an HA product used in the treatment of joint diseases, such as osteoarthritis, and viscoelastic products used in eye surgery. The ophthalmic products include AMVISC and AMVISC Plus product line, CoEase, STAARVISC-II, and ShellGel. Its injectable ophthalmic viscoelastic products are molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation. The company operates in the United States and Canada, the United Kingdom, Italy, and other European countries, Turkey, and parts of the Middle East. Anika Therapeutics was founded in 1983 and is headquartered in Woburn, Massachusetts.
NORTHFIELD LABORATORIES INC (NFLD)
Northfield Laboratories, Inc., a development stage company, engages in the research, development, testing, manufacture, marketing, and distribution of hemoglobin-based blood substitute products. It primarily develops PolyHeme, an oxygen-carrying blood substitute for the treatment of urgent life-threatening blood loss in trauma and resultant surgical settings. The PolyHeme is in Phase III clinical trial. The company was founded in 1985 and is based in Evanston, Illinois.
QIAGEN N.V., through its subsidiaries, provides enabling technologies and products for the separation, purification, and handling of nucleic acids and proteins. It offers a portfolio of consumable products for nucleic acid and protein separation, purification and handling, and nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products, and related services. Its consumable products applications include plasmid deoxyribonucleic (DNA) acid purification; ribonucleic acid (RNA) stabilization and purification; genomic and viral nucleic acid purification; nucleic acid transfection; PCR amplification; reverse transcription; DNA cleanup after PCR and sequencing; DNA cloning and protein purification. Its BioRobot systems offer automation of nucleic acid preparation in low, medium, or high throughput scale, as well as reaction set-up and other laboratory tasks. The company also offers custom services, small interfering RNA synthesis, whole genome amplification services, DNA sequencing, and noncGMP and cGMP DNA production on a contract basis. The company sells its products to academic research markets, and pharmaceutical and biotechnology companies, as well as developing commercial markets, including applied testing markets, clinical research, nucleic acid-based molecular diagnostics, and genetic vaccination, and gene therapy. It operates in the United States, Germany, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, Sweden, and the Netherlands. QIAGEN has a strategic alliance with Eppendorf AG to co-develop and co-market complementary and optimized products. The company was co-founded in 1984 by Detlev H. Riesner and Metin Colpan. QIAGEN is headquartered in Venlo, The Netherlands.
XenoPort, Inc. develops and markets applications to enhance bioavailability of drugs. The company's product Transported Prodrug uses transporter genomics, assay technology, and proprietary chemistries to introduce therapeutic molecules into cells. Additionally, it provides solution to improve expiring drugs. XenoPort was founded in 1999 and is headquartered in Santa Clara, California.
CYPRESS BIOSCIENCE INC (CYPB)
Cypress Bioscience, Inc., a biotechnology company, develops products for the treatment of Functional Somatic Syndromes, such as Fibromyalgia Syndrome (FMS), as well as other related chronic pain and central nervous system disorders. It develops Milnacipran, a norepinephrine serotonin reuptake inhibitors agent for the treatment of FMS. As of March 31, 2005, Milnacipran was in a Phase III trial for the treatment of FMS. Milnacipran is a compound, which exerts its effect by inhibiting the reuptake of both norepinephrine and serotonin, two neurotransmitters in regulating pain and mood. The company has a collaboration agreement with Forest Laboratories, Inc.; and a reformulation and new product agreement with Collegium Pharmaceutical, Inc. Cypress Bioscience is based in San Diego, California.
QLT, Inc., a bio-pharmaceutical company, engages in the discovery, development, and commercialization of therapies in the fields of ophthalmology, dermatology, oncology, and urology primarily in North America. The company's products include Visudyne, which is used for the treatment of choroidal neovascularization; and Eligard products that are used for prostate cancer incorporate a leutinizing hormone-releasing hormone agonist, or LHRH agonist, known as leuprolide acetate with its proprietary Atrigel drug delivery system. QLT also offers generic dermatology products, including lidocaine and prilocaine cream, erythromycin and benzoyl peroxide topical gel, mometasone furoate ointment, betamethasone dipropionate cream, and fluticasone propionate cream. In addition, it provides dental products, which include Atridox and Atrisorb-D. The company has strategic alliances with Novartis Ophthalmics. QLT was formed in 1981 and is headquartered in Vancouver, Canada.
Biogen Idec, Inc. engages in the development, manufacture, and commercialization of novel therapies worldwide. It offers AVONEX, RITUXAN, TYSABRI, ZEVALIN, and AMEVIVE products. The company's AVONEX is approved for the treatment of relapsing forms of multiple sclerosis; RITUXAN is used in the treatment of certain B-cell non-Hodgkin's lymphomas (NHL) or B-cell NHLs; TYSABRI is approved to treat relapsing forms of MS to reduce the frequency of clinical relapses; ZEVALIN used in the treatment of cancer; and AMEVIVE treats adult patients with moderate-to-severe chronic plaque psoriasis. Biogen Idec has collaborations with Genentech, Inc.; Vernalis plc; Elan Corporation, plc; Fumapharm AG; ImmunoGen, Inc.; Sunesis Pharmaceuticals, Inc.; Cellectis SA; and Zenyaku Kogyo Co., Ltd. The company was founded in 1985. It was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec, Inc. in 2003. Biogen Idec is headquartered in Cambridge, Massachusetts.
DYADIC INTERNATIONAL INC (DIL)
Dyadic International, Inc. engages in the development and distribution of specialty enzymes and related products for sale to the textile, food and feed, starch, pulp and paper, and other industries in the United States of America, Hong Kong, Poland, and the Netherlands. The company focuses on functional proteomics through the discovery, development, and manufacturing of novel products, including enzymes and proteins, derived from the genes of complex living organisms. Using its proprietary platform technologies for gene discovery and gene expression, Dyadic develops additional biological products, such as proteins, enzymes, polypeptides, and small molecules for use by itself and for applications in large segments of the agricultural, industrial, chemical, and pharmaceutical industries. Dyadic International is based in Jupiter, Florida.
CAMBREX CORPORATION (CBM)
Cambrex Corporation and its subsidiaries provide products and services to accelerate drug discovery, development, and manufacturing processes for human therapeutics worldwide. It operates through three segments: Bioproducts, Biopharma, and Human Health. The Bioproducts segment offers research products and therapeutic application products; The Biopharma segment provides contract biopharmaceutical process development and manufacturing services; and The Human Health segment produces active pharmaceutical ingredients and pharmaceutical intermediates for use in the production of prescription and over-the-counter drug products, as well as other custom chemicals derived from organic chemistry. Cambrex Corporation sells its products through its direct sales force, independent distributors, and its e-commerce Web site to pharmaceutical and biopharmaceutical companies, generic drug companies, biotechnology companies, and research organizations. The company was founded in 1981 and is based in East Rutherford, New Jersey.
GPC Biotech AG, a biopharmaceutical company, engages in the discovery and development of drugs to treat cancer. Its lead product candidate is satraplatin, an oral platinum-based compound intended for use as a chemotherapy drug. Satraplatin is being evaluated in a phase III registrational trial for second-line treatment of hormone refractory prostate cancer. The company's second product candidate, 1D09C3, is a monoclonal antibody intended for the treatment of selected leukemias and lymphomas, including nonHodgkin's lymphoma. Its another product candidate, RGB-286199, is a lead compound in a family of small molecule compounds that inhibit the cell cycle, which is essential for tumor growth. RGB-286199 is in preclinical development. GPC Biotech has a strategic alliance with ALTANA Pharma AG, which encompasses a technology transfer component, as well as research collaboration; and a co-development and license agreement with Pharmion Corp. for satraplatin, the oral platinum-based compound in advanced clinical development. The company was co-founded by Elmar Maier, Mirko Scherer, Sebastian Meier-Ewert, and David R. Bancroft as RM 102 Vermôgensverwaltungs GmbH in January 1997 and changed its name to Genome Pharmaceuticals Corporation GmbH in August 1997. The name was further changed to GPC Aktiengesellschaft Genome Pharmaceuticals Corporation in 1998 and to GPC Biotech AG in 2000. GPC Biotech is headquartered in Munich, Germany.
ALNYLAM PHARMACEUTICALS INC (ALNY)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products based on RNA interference (RNAi) in the United States. The company is developing a pipeline of RNAi products using Direct RNAi to treat ocular, central nervous system, and respiratory diseases; and Systemic RNAi to treat a range of diseases, including oncology, metabolic, and autoimmune diseases. Its RNAi development programs are focused on an eye disease, known as age-related macular degeneration; and on a lung infection caused by a virus, known as human respiratory syncytial virus. The company also has multiple preclinical programs in Direct RNAi focused on a central nervous system disorder, known as Parkinson's disease; spinal cord injury; and a genetic disease, known as cystic fibrosis. In addition, Alnylam offers nontherapeutic license agreements to life science reagent and service providers. The company has strategic alliances and research collaborations with Merck & Co., Inc.; Medtronic, Inc.; Cystic Fibrosis Foundation Therapeutics, Inc.; Mayo Foundation for Medical Education and Research; Novartis AG; and Mayo Clinic Jacksonville. Alnylam was founded by Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore in 2002. The company is headquartered in Cambridge, Massachusetts.
Medarex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of human antibody-based therapeutic products. The company's UltiMAb human antibody development system enables to create and develop antibodies products for a range of diseases, including cancer and rheumatoid arthritis, as well as for other inflammatory, autoimmune, and infectious diseases. As of March 31, 2005, the company had 22 antibody product candidates generated from its UltiMAb Human Antibody Development System that were in human clinical trials for the treatment of a range of diseases. In addition, its preclinical and clinical development of therapeutic antibody products pipeline include product candidates MDX-010, which is developing jointly with Bristol-Myers Squibb Company, for the treatment of metastatic melanoma and other cancers; MDX-060 for lymphomas; MDX-070 for prostate cancer; MDX-214 for cancer; and MDX-1307 for genitourinary and breast cancers. Further, the company is developing MDX-066, jointly with The Massachusetts Biologic Laboratories of the University of Massachusetts Medical School, for the treatment of Clostridium difficile associated diarrhea; as well as MDX-018, jointly developing with Genmab A/S for autoimmune disease. As of March 1, 2005, Medarex had approximately 50 partnerships with pharmaceutical and biotechnology companies to jointly develop and commercialize products or to enable other companies to use its proprietary technology in their development of new therapeutic products. The company also has a strategic alliance agreement with Devon Health Services, Inc. to form a clinical trials organization. Medarex was founded in 1987 and is headquartered in Princeton, New Jersey.
FORBES MEDI-TECH INC (FMTI)
Forbes Medi-Tech, Inc., a life sciences company, engages in the research, development, and commercialization of products for the prevention and treatment of cardiovascular disease. It develops cholesterol-lowering agents used both as pharmaceutical therapeutics and functional food ingredients. The company's lead drug candidate is FM-VP4, a cholesterol-lowering prescription pharmaceutical candidate, which completed a Phase II clinical trial in Europe. FM-VP4 is a cholesterol absorption inhibitor, a relatively new class of cholesterol-lowering pharmaceutical that would have therapeutic applications alone or in conjunction with other cholesterol-lowering therapies. The company also markets two nutraceutical products, Reducol and Phyto-S-Sterols. These products are plant sterol-based cholesterol-lowering food and dietary supplement ingredients derived from by-products of the forestry industry. Its drug development program includes FM-VA12, a single molecular entity that has been shown in animal studies to inhibit cholesterol absorption; and FM-VP24, an analogue, which early stage research shows inhibits cholesterol absorption while also exhibiting anti-inflammatory activity. Forbes has strategic partnership with Chusei (U.S.A.), Inc. The company was incorporated in 1985 as Amber Resources, Ltd. and changed its name to Forbes Medi-Tech, Inc. in 1992. Forbes is headquartered in Vancouver, Canada.
InterMune, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies in pulmonology and hepatology. The company markets various products, including Actimmune (interferon gamma-1b) for the treatment of severe osteopetrosis, and chronic granulomatous disease; Infergen (consensus interferon alfacon-1) for the treatment of patients with compensated liver disease with chronic hepatitis C virus infections; and Amphotec (amphotericin B cholesteryl sulfate complex for injection) for the treatment of invasive aspergillosis. In pulmonology area, InterMune develops Actimmune, a second phase III clinical trial, which is used for the treatment of patients with idiopathic pulmonary fibrosis; and interferon gamma-1b under the name Imukin. In hepatology area, it is developing once-daily Infergen in combination with ribavirin therapy for the treatment of patients suffering from chronic HCV infections; Infergen in combination with Actimmune, which is in Phase IIb clinical trial for the treatment of hepatitis C nonresponders; and PEG-Alfacon-1 that completed phase I clinical trial for the treatment of chronic HCV infections. In addition, the company evaluates Actimmune in patients with ovarian cancer in a Phase III trial. InterMune has collaboration and licensing agreements with Boehringer Ingelheim International GmbH; Maxygen Holdings, Ltd.; and Array BioPharma, Inc. The company was incorporated in 1998 and is headquartered in Brisbane, California.
Nutrition 21, Inc., a nutritional bioscience company, engages in the research, development, and commercialization of chromium-based nutrition products. It develops and markets Chromax chromium picolinate to vitamin and supplement market for both human and animal applications. The company's products are used in the improving the structure or function of the body, and in the prevention and treatment of metabolic diseases, such as diabetes, insulin resistance, obesity, depression, and cardiovascular diseases. The company has a strategic alliance with XLHealth to incorporate Diachrome, a dietary management product for diabetes, into its treatment protocol. Nutrition 21 was incorporated as Applied Microbiology, Inc. in 1983 and is headquartered in Purchase, New York.
VIROPHARMA INCORPORATED (VPHM)
ViroPharma Incorporated, a pharmaceutical company, engages in the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. It markets and sells Vancocin Pulvules HCl, the oral capsule formulation, in the United States and its territories. Oral Vancocin is a potent antibiotic to treat antibiotic-associated pseudomembranous and enterocolitis. The company focuses on product development activities on viral diseases, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. Its products under core development program include CMV with an initial focus on CMV infections in recipients of hematopoietic stem cell/bone marrow transplants, and HCV. Noncore development programs target picornaviruses with intranasal pleconaril. The company has strategic relationships with Glaxo SmithKline, Wyeth, Schering-Plough, and Sanofi-Aventis. ViroPharma was incorporated in 1994 and is based in Exton, Pennsylvania.
PEREGRINE PHARMACEUTICALS INC (PPHM)
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for the treatment of cancer, viruses, and other diseases using targeted antibodies. The company's products portfolio includes Cotara for brain cancer, which is in Phase II/III registration trial, and Tarvacin, an anti-phospholipid therapy agent for the treatment of solid tumors and chronic hepatitis C virus infection. Its vascular research programs fall under various technology platforms, including tumor necrosis therapy, antiphospholipid therapy, vascular targeting agents, antiangiogenesis, and vasopermeation enhancement agent technology. In addition, the company, through its wholly owned subsidiary, Avid Bioservices, Inc., provides a range of contract manufacturing services, including contract manufacturing of antibodies and proteins, cell culture development, process development, and testing of biologics for biopharmaceutical and biotechnology companies. The company was founded in 1981 as Techniclone International Corporation. It changed its name to Techniclone Corporation in 1997 and to Peregrine Pharmaceuticals, Inc. in 2000. Peregrine Pharmaceuticals is based in Tustin, California.
LIFECORE BIOMEDICAL INC (LCBM)
Lifecore Biomedical, Inc. engages in the development, manufacture, and marketing of biomaterials and medical devices for use in various surgical markets. It operates in two segments, Hyaluronan and Oral Restorative. The Hyaluronan segment develops and manufactures products utilizing hyaluronan, a naturally occurring polysaccharide that is distributed in the extracellar matrix of connective tissues in both animals and humans. Hyaluronan is also used as a component in ophthalmic, orthopedic, and veterinary medical devices. It also offers FeHA Adhesion Prevention Solution that reduces the incidence of tissue adhesions following surgical trauma, as well as hyaluronan to other medical applications, such as wound care, aesthetic surgery, medical device coatings, tissue engineering, drug delivery, and pharmaceuticals. This segment markets its products through original equipment manufacturers and contract manufacturing alliances in ophthalmologic and orthopedic surgery and veterinary medicine. The Oral Restorative segment develops and markets precision surgical and prosthetic devices for the restoration of damaged or deteriorating dentition and associated support tissues. Its dental implants are permanently implanted in the jaw for tooth replacement therapy as long-term support for crowns, bridges, and dentures. This segment also offers bone regenerative products for the repair of bone defects resulting from periodontal disease and tooth loss; and professional support services to its dental surgery clients through education curricula. It markets its products directly to clinicians and dental laboratories in the United States, Germany, Italy, Sweden, and France; and through distributorship arrangements in other foreign locations. The company was incorporated as American Medical Research, Inc. in 1965 and changed its name to DIAGNOSTIC, INC. in 1968. Further, it changed its name to Lifecore Biomedical, Inc. in 1987. Lifecore Biomedical is headquartered in Chaska, Minnesota.
CITIGROUP GLOBAL MARKETS (CAQ)
No description available.
XOMA, Ltd., a biopharmaceutical company, engages in the development and manufacture of antibodies and other genetically-engineered protein products to treat immunological and inflammatory disorders, cancer, and infectious diseases. The company's proprietary and collaborative product development programs include RAPTIVA, a humanized therapeutic monoclonal antibody, for the treatment of adults for moderate to severe plaque psoriasis; CHIR-12.12, an anti-CD40 antagonist antibody intended as a treatment for B-cell malignancies; and NEUPREX, a Phase II clinical trial product, IV formulation of rBPI21, a modified recombinant fragment of bactericidal/permeability-increasing protein for multiple anti-infective and antiendotoxin indications. Its development products also comprise MLN2222, a Phase II clinical trial product, a complement inhibitor under development to reduce the incidence of complications in patients undergoing surgical procedures involving the use of cardiopulmonary bypass; Gastrin, a preclinical antigastrin antibody, for Gastric cancers; ING-1, a Phase I clinical trial product, Human Engineered antibody to Ep-CAM for Adenocarcinomas; and XMP.629, a topical formulation of BPI derived antimicrobial peptide fro acne. XOMA, Ltd. also licenses its proprietary technologies relating to bacterial expression of recombinant pharmaceutical products, as well as its Human Engineering technology that allows modification of any nonhuman monoclonal antibody to reduce or eliminate detectable immunogenicity in humans to biotechnology and pharmaceutical companies. It has collaboration and license agreements with Genentech, Inc.; Chiron Corporation; Zephyr Sciences, Inc.; Millennium Pharmaceuticals, Inc.; Aphton Corporation; Merck & Co., Inc.; Lexicon Genetics Incorporated; Cubist Pharmaceuticals, Inc.; and Triton BioSystems, Inc. The company was founded by Patrick J. Scannon. XOMA, Ltd. was incorporated in 1981 and is headquartered in Berkeley, California.
SEQUENOM, Inc., a genetics company, provides genetic analysis products that translate genomic science into superior solutions for biomedical research and molecular medicine. It primarily offers MassARRAY system that includes hardware, software, and consumable products. The MassARRAY system is a DNA analysis platform that measures the amount of genetic target material and variations therein. The system delivers data from biological samples and genetic target material that is available in trace amounts. The company offers its products primarily to pharmaceutical and biotechnology companies, laboratories, and governmental and other research institutions in North America, Europe, and Asia. It has strategic collaboration agreements with Bioscientia, Siemens Medical Solutions, and Procter & Gamble Pharmaceuticals. SEQUENOM was established in 1994 and is headquartered in San Diego, California.
CHARLES RIVER LABORATORIES INTERNATIONAL INC (CRL)
Charles River Laboratories International, Inc. provides research tools and integrated support services that enable the drug discovery and development process. It operates in three segments: Research Models and Services (RMS), Preclinical Services, and Clinical Services. RMS segment produces and sells research models, primarily genetically and virally defined purpose-bred rats and mice. It also provides various related services that are designed to assist its customers in screening drug candidates. In addition, RMS offers transgenic services, laboratory services, consulting and staffing services, vaccine support, and in vitro technology services. Preclinical Services segment offers services in the areas, such as general and specialty toxicology, pathology, interventional and surgical, biopharmaceutical, pharmacokinetic and metabolic analysis, and bioanalytical chemistry. Clinical Services segment conducts Phase I clinical trials; and provides Phase II-IV clinical trials management services, which include testing, medical data sciences services, and regulatory support. Charles River Laboratories sells its products and services primarily through its direct sales force supplemented by a network of international distributors in the United States, Europe, and Japan. The company's customer base includes pharmaceutical, biotechnology, and animal health and medical device companies, as well as various government agencies, hospitals, and academic institutions. It operates approximately 100 facilities in 20 countries worldwide. Charles River Laboratories was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Embrex, Inc., an agricultural biotechnology company provides vaccine and mechanical products for bird health. The company develops and commercializes the Inovoject system, a proprietary, automated in-the-egg injection system, which can inoculate 20,000 to 60,000 eggs per hour and eliminates the need for manual, post-hatch injection of certain vaccines. It offers Egg Remover system to remove infertile and early-dead eggs from incubator trays prior to transfer or inoculation through the Inovoject system; Vaccine Saver option for the Inovoject system that identifies infertile and early-dead eggs and selectively prevents vaccination of these eggs. Embrex has also developed an antigen-antibody complex technology used for the development of certain avian vaccines. It also markets Bursaplex for protection against avian infectious bursal disease; and Newplex for protection against Newcastle disease. Embrex primarily markets its products to commercial poultry producers and human flu vaccine producers. Embrex was incorporated in 1985 and is headquartered in Durham, North Carolina.
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics primarily related to the treatment of serious men's health conditions and oncology. The company's drug discovery and development programs focus on small molecules that selectively modulate the effects of estrogens and androgens, two essential classes of hormones. It markets FARESTON, a toremifene citrate tablets, for the treatment of metastatic breast cancer. GTx develops ACAPODENE for two separate indications in men, a Phase III clinical trial product, for the prevention of prostate cancer in high risk men, and a Phase III clinical trial product for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer. The company also develops andarine, a selective androgen receptor modulator (SARM); as well as a second SARM, ostarine, for andropause and other chronic conditions related to aging, including sarcopenia. Further, its preclinical pipeline includes the specific product candidates prostarine, a SARM for benign prostatic hyperplasia, and andromustine, an anticancer drug, for hormone refractory prostate cancer. Additionally, it develops andarine for the treatment of cachexia from various types of cancer. The company has joint collaboration and license agreement with Ortho Biotech Products L.P. for the clinical development of andarine and specified backup SARM compounds. It also has collaboration agreements with Hybritech, Inc., diaDexus, Inc., and Tessera, Inc. GTx was co-founded by Mitchell S. Steiner and Marc S. Hanover in 1997. The company is based in Memphis, Tennessee.
Crucell N.V. engages in the discovery, development, and production of various biopharmaceutical products for the prevention and treatment of infectious diseases using its proprietary technologies. It develops vaccines and antibodies against influenza, West Nile virus, Ebola, malaria, tuberculosis, and rabies using PER.C6, AdVac, and MAbstract technologies. The company's PER.C6 technology encompasses a human cell line production system to develop biopharmaceutical products. Its AdVac technology is a recombinant vector technology that develops novel adenoviral-based products. Crucell's MAbstract phage antibody display technology is used to discover disease associated molecules and develop human antibodies. The company licenses its technologies to pharmaceutical and biotechnology companies. Crucell has a research and licensing agreement with ACE BioSciences A/S to discover antibody therapies to combat serious iatrogenic infections, including those caused by antibiotic-resistant bacteria; and a research and development agreement with the Walter Reed Army Institute of Research to evaluate Crucell's PER.C6 technology for the development of vaccines against the flaviviruses dengue fever and Japanese encephalitis. The company is headquartered in Leiden, the Netherlands.
GENZYME CORPORATION (GENZ)
Genzyme Corporation operates as a biotechnology company. Its products and services focuses on rare genetic disorders, renal disease, kidney disease, cancer, orthopaedics, organ transplant, and diagnostic and predictive testing. The company operates in five segments: Renal, Therapeutics, Transplant, Biosurgery, and Diagnostics/Genetics. The Renal unit develops, manufactures, and distributes products that treat patients suffering from renal diseases, including chronic renal failure. The Therapeutics unit offers therapeutic products for genetic diseases; and other chronic debilitating diseases, including lysosomal storage disorders and other specialty therapeutics. The Transplant unit provides therapeutic products that address pretransplantation, prevention, and treatment of acute rejection in organ transplantation, as well as other auto-immune disorders. The Biosurgery unit develops, manufactures, and distributes biotherapeutics and biomaterial products, with an emphasis on products that meet medical needs in orthopaedics and broader surgical areas. The Diagnostics/Genetics unit offers vitro diagnostic products; and testing services for the oncology, and prenatal and reproductive markets. The company offers its products primarily to physicians, hospitals, and treatment centers in various countries, including the United States, the United Kingdom, Ireland, the Netherlands, Belgium, France, Canada, Switzerland, and Germany. Genzyme Corp. has an agreement with RenaMed Biologics, Inc. to jointly develop and commercialize RenaMed's Bio-Replacement Therapy for the treatment of acute renal failure; a collaboration with De Novo Pharmaceuticals, Ltd. to apply De Novo's molecular structure generating technology to focus on a disease target of interest to Genzyme; and a collaboration agreement with Epiontis GmbH to develop quality control tests for Genzyme's cartilage repair product Carticel. The company was founded in 1981 and is based in Cambridge, Massachusetts.
ZymoGenetics, Inc. engages in the discovery, development, and commercialization of therapeutic protein-based products for the treatment of human diseases. Its products include Novolin and NovoRapid marketed worldwide for the treatment of diabetes; NovoSeven marketed worldwide for the treatment of hemophilia; Regranex for the treatment of wound healing; GlucaGen for use as an aid for gastrointestinal motility inhibition and for the treatment of severe hypoglycemia in diabetic patients treated with insulin; and Cleactor for the treatment of myocardial infarction or heart attacks. The company's product pipeline comprises rhThrombin, TACI-Ig, and IL-21. rhThrombin is a topical hemostatic agent intended for the control of bleeding during surgical procedures has completed Phase 2 clinical trial. TACI-Ig is a soluble receptor for the treatment of autoimmune diseases and is developed in collaboration with Serono S.A. IL-21 is a protein for the treatment of cancer. ZymoGenetics was co-founded by Earl W. Davie, Benjamin D. Hall, and Michael Smith in 1981. The company is headquartered in Seattle, Washington.
PHARMACOPEIA DRUG DISCOVERY INC (PCOP)
Pharmacopeia Drug Discovery, Inc., a biopharmaceutical company, engages in the discovery and development of small molecule therapeutics primarily to address significant medical needs. Using proprietary technologies and processes, Pharmacopeia discovers and develops novel drug candidates to advance internally, as well as with strategic partners. Pharmacopeia's product pipeline includes four compounds in human clinical trials (all Phase I) with various partners, including a compound targeting rheumatoid arthritis in collaboration with Bristol Myers Squibb, a compound targeting asthma and allergies in collaboration with Daiichi Pharmaceutical Corporation, a compound targeting respiratory diseases in collaboration with Schering-Plough, and a compound targeting inflammation in collaboration with Schering-Plough. The company also has 6 additional partnered compounds in preclinical development; 4 internal (nonpartnered) drug candidates; and approximately 20 partnered and internal discovery-stage programs. Pharmacopeia was founded in 1993 and is headquartered in Cranbury, New Jersey.
MEDICIS PHARMACEUTICAL CORPORATION (MRX)
Medicis Pharmaceutical Corporation, a specialty pharmaceutical company, focuses on the development and marketing of products for the treatment of dermatological, aesthetic, and podiatric conditions in the United States and Canada. It offers a range of products addressing various conditions, including acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, eczema, skin and skin-structure infections, seborrheic dermatitis, and cosmesis. The company's product portfolio comprises DYNACIN, an oral adjunctive treatment for moderate to severe acne; LOPROX, a topical treatment for certain fungal and yeast infections; OMNICEF, a patented oral cephalosporin for skin and skin-structure infections; PLEXION, topical treatments for rosacea and acne-related conditions; RESTYLANE, an injectable gel for treatment of fine lines and wrinkles, shaping facial contours, and correcting deep facial folds; TRIAZ, topical patented gel, cleanser, and patent-pending pad treatments for acne; and VANOS, topical corticosteroid for the treatment of plaque type psoriasis in adult patients. It also offers PERLANETM and RESTYLANE FINE LINES, which are injectable, transparent, and nonanimal-stabilized-hyaluronic acid gels for the treatment of fine lines and wrinkles, and correcting deep facial folds. The company's nondermatological product line includes AMMONUL, as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle; and BUPHENYL, an adjunctive maintenance therapy for urea cycle disorders. Its customers include wholesale pharmaceutical distributors and other drug chains. The company has a strategic alliance with aaiPharma, Inc. Medicis Pharmaceutical was founded in 1987 and is headquartered in Scottsdale, Arizona.
Genentech, Inc., a biotechnology company, engages in the discovery, development, manufacture, and commercialization of biotherapeutics for medical needs. It manufactures and commercializes multiple products for a variety of medical conditions, including cancer, heart attack, allergic asthma, psoriasis, stroke, growth hormone deficiency, and cystic fibrosis in the United States. The company's product portfolio comprises Rituxan, an anti-CD20 antibody; Herceptin, an anti-HER2 antibody; Nutropin Depot growth hormone; Nutropin growth hormone; Protropin growth hormone; Nutropin AQ, a liquid formulation growth hormone; TNKase, a thrombolytic agent; Activase, a tissue plasminogen activator; Cathflo Activase; Pulmozyme, an inhalation solution; Xolair, an anti-IgE antibody; Raptiva, an anti-CD11a antibody; and Avastin, a humanized antibody. It also licenses various additional products to other companies. Genentech's products under development cover various medical conditions, including cancer, respiratory disorders, cardiovascular diseases, endocrine disorders, and inflammatory and immune problems. In addition, the company, jointly with Rinat Neuroscience Corp., develops RI 624, a humanized monoclonal antibody that blocks nerve growth factor. Genentech has collaboration agreements with Array Biopharma, Inc. and Curis, Inc. for the discovery of targeted small-molecule drugs for the treatment of cancer; with Accelerate Brain Cancer Cure relating to Avastin in patients with glioblastoma multiforme, a form of brain cancer; with PIramed, Ltd. to develop anti-cancer drugs; and with Lexicon Genetics, Inc. to discover and develop biotherapeutic drugs. The company's products are sold primarily to wholesalers, specialty distributors, or directly to hospital pharmacies. Genentech was founded by Robert A. Swanson and Herbert W. Boyer in 1975. The company is headquartered in South San Francisco, California.
ONCOLYTICS BIOTECH INC (ONCY)
No description available.
Amgen, Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. The company markets human therapeutic products in the areas of nephrology, supportive cancer care, and inflammatory disease. Its products primarily include EPOGEN, Aranesp, Neulasta, NEUPOGEN, and ENBREL, which is marketed under a co-promotion agreement with Wyeth in the United States and Canada. EPOGEN and Aranesp stimulate the production of red blood cells to treat anemia. Neulasta and NEUPOGEN selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections. ENBREL blocks the biologic activity of tumor necrosis factor (TNF) by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. It sells its products to healthcare providers, including clinics, hospitals, and pharmacies primarily in the United States, Europe, Canada, and Australia. Amgen has collaboration and license agreement with Memory Pharmaceuticals Corp. to produce drugs for neurological and psychiatric disorders; and a drug-discovery agreement with Galapagos Genomics NV. The company was established by Bill Bowes, Franklin Johnson, Sam Wohlsteadter, and Raymond Baddour in 1980. Amgen is headquartered in Thousand Oaks, California.
Renovis, Inc., a biopharmaceutical company, develops drugs to treat neurological diseases and disorders. The company develops Cerovive, a Phase III SAINT II trial development product, a radical trapping neuroprotectant for the treatment of acute ischemic stroke. It also develops REN-1654, a Phase II clinical trial product, an oral drug candidate for neuropathic pain; and REN-850, a Phase Ia clinical trial product, an oral drug candidate for multiple sclerosis. In addition, Renovis conducts preclinical research and development activities in the areas of neuroprotection and pain to identify product candidates for clinical development. The company has a collaborative research, development, and license agreement with Genentech, Inc.; and collaboration and licensing agreement with Pfizer, Inc. Renovis was incorporated in 2000 and is headquartered in San Francisco, California.
HEMISPHERX BIOPHARMA INC (HEB)
Hemispherx Biopharma, Inc., a biopharmaceutical company, engages in the clinical development and manufacture of drugs for the treatment of viral and immune-based chronic disorders. Its products primarily include Ampligen and Alferon. Ampligen is a Phase III completed product for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), human immunodeficiency virus (HIV), and HIV/Hepatitis C co-infection. Alferon is an injectable formulation of natural alpha interferon for use in the treatment of genital warts. The company's Alferon is also in clinical development for the treatment of hepatitis C, multiple sclerosis, HIV, west Nile virus, and severe acute respiratory syndrome. In addition, the company's Alferon LDO is an experimental low-dose, oral liquid formulation of natural alpha interferon, which would be used for the treatment of viral diseases. Hemispherx Biopharma is headquartered in Philadelphia, Pennsylvania.
REPLIGEN CORPORATION (RGEN)
Repligen Corporation develops novel therapeutics for the treatment of diseases of the central nervous system. It sells Protein A products, which are used in the production of monoclonal antibodies and SecreFlo, a synthetic form of the hormone secretin, which is used as an aid in the diagnosis of certain pancreatic disorders. The company sells Protein A products to chromatography companies, diagnostics companies, biopharmaceutical companies, and laboratory researchers primarily through value-added resellers and distributors in the United States and internationally. It markets SecreFlo directly to gastroenterologists in the United States. The company also conducts drug development programs for diseases, such as schizophrenia, obsessive-compulsive disorder, bipolar disorder, and neurodegeneration. Repligen has a development agreement with the Stanley Medical Research Institute for a Phase 2 clinical trial of uridine in bipolar depression. The company was founded in 1981 and is based in Waltham, Massachusetts.
TECHNE CORPORATION (TECH)
TECHNE Corporation, through its subsidiaries, engages in the development and manufacture of biotechnology products and hematology calibrators and controls. The company operates in two divisions, Biotechnology and Hematology. The Biotechnology division engages in the development and manufacture of cytokines and enzymes, antibodies, assay kits, clinical diagnostic kits, flow cytometry products, and intracellular cell signaling products. These products are sold to biomedical researchers and clinical research laboratories. The Hematology division develops and manufactures whole blood hematology controls and calibrators, linearity and reportable range controls, whole blood reticulocyte controls, whole blood flow cytometry controls, whole blood glucose/hemoglobin control, erythrocyte sedimentation rate control, and multipurpose platelet reference controls. These products are sold to hospitals and clinical laboratories to check the performance of hematology instruments. In addition, the company distributes biotechnology products in Europe. The company was founded in 1976 and is based in Minneapolis, Minnesota.
IMCLONE SYSTEMS INCORPORATED (IMCL)
ImClone Systems Incorporated, a biopharmaceutical company, engages in developing and commercializing biologic medicines in the area of oncology in the United States. Its research and development programs include growth factor blockers and angiogenesis inhibitors. The company's primary product, ERBITUX, is an antibody for use in combination with irinotecan in the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer who are refractory to irinotecan-based chemotherapy and for use as a single agent in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are intolerant to irinotecan-based chemotherapy. ERBITUX binds specifically to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) on both normal and tumor cells, and inhibits the binding of epidermal growth factor and other ligands, such as transforming growth factor-alpha. The company also conducts registration studies evaluating ERBITUX for the treatment of colorectal, head and neck, lung, and pancreatic cancers, as well as other indications. In addition, it develops cancer vaccines, as well as investigational inhibitors of angiogenesis, which could be used to treat various kinds of cancer and other diseases. ImClone Systems has collaboration agreements with Bristol-Myers Squibb Company for developing and promoting ERBITUX in the United States, Canada, and Japan; and with Merck KGaA for the development and commercialization of the recombinant gp75 antigen product candidate and ERBITUX. The company was founded in 1984 and is headquartered in New York City.
Insmed Incorporated, a biopharmaceutical company, engages in the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders. Its lead product includes recombinant human insulin-like growth factor-I bound to recombinant human insulin-like growth factor binding protein-3 (rhIGF-I/rhIGFBP-3), a Phase III clinical trial product, which would be used for the treatment of severe growth disturbance due to growth hormone insensitivity syndrome. The company's research and development stage products include rhIGFBP-3, for the treatment of various cancers; and INSM-18, for the treatment of various tumors. The company has strategic relationships with Fujisawa Pharmaceutical Co., Ltd.; Tzamal Pharmaceutical; Pharmacia, Inc.; and Avecia Limited. Insmed was incorporated in 1999 and is based in Glen Allen, Virginia.
INVITROGEN CORPORATION (IVGN)
Invitrogen Corporation provides products and services that support academic and government research institutions, and pharmaceutical and biotech companies in the United States and Europe. It operates in two segments, BioDiscovery and BioProduction. BioDiscovery segment includes functional genomics, cell biology, and drug discovery product lines. This segment also comprises a range of enzymes, nucleic acids, and other biochemicals and reagents. The company also offers software through this segment that enables analysis and interpretation of genomic, proteomic, and other biomolecular data for application in pharmaceutical, therapeutic, and diagnostic development. BioProduction segment includes various cell culture products and biological testing services. Its products comprise sera, cell, and tissue culture media; reagents used in both life sciences research and in processes to grow cells in the laboratory and to produce pharmaceuticals; and other materials made through cultured cells. BioProduction's services include testing to ensure that biologics are free of disease-causing agents or do not cause adverse effects; characterization of products' chemical structures; development of formulations; and validation of purification processes under regulatory guidelines. It also manufactures biologics on behalf of clients both for use in clinical trials and for the worldwide commercial market. The company serves the life sciences research market; biotechnology, pharmaceutical, energy, agricultural, and chemical companies; and industries that apply genetic engineering to the commercial production. It supplies its products through its own sales force and agents or distributors. Invitrogen has collaboration with Families of Spinal Muscular Atrophy to identify biological targets that are linked to the causes and symptoms of spinal muscular atrophy. The company was founded in 1987 and is headquartered in Carlsbad, California.
INCYTE CORPORATION (INCY)
Incyte Corporation engages in the discovery and development of small molecule drugs to treat medical conditions, including the infection with human immunodeficiency virus (HIV), inflammatory disorders, cancer, and diabetes. Its primary product candidate Reverset is a nucleoside analog reverse transcriptase inhibitor for use in combination with other antiviral drugs for patients with HIV infections, and is in phase IIb clinical trials. In addition, the company's drug discovery programs underway include CCR2 Receptor Antagonist Program and Sheddase Inhibitor Program. CCR2 Receptor Antagonist Program is focused on developing antagonists to a key chemokine receptor involved in inflammation called CCR2. CCR2 is a chemokine receptor found on monocytes that controls their migration into sites of inflammation. The primary products candidate form this program is in phase IIa clinical trial in patients with rheumatoid arthritis. The Sheddase Inhibitor Program involves sheddase inhibitors that would have application in the treatment of breast cancer and other tumor types and is in phase I clinical trials. The company markets its products in the United States and in Austria, Belgium, Canada, France, Denmark, Germany, Israel, Japan, the Netherlands, Sweden, Switzerland, and the United Kingdom. Incyte has collaborative agreement with Pharmasset, Inc.; Senomyx, Inc.; Genomic Health, Inc.; Pfizer, Inc.; and Medarex, Inc. Incyte was founded in 1991 and is headquartered in Wilmington, Delaware.
METABASIS THERAPEUTICS INC (MBRX)
Metabasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs principally to treat metabolic diseases, cancer, and certain other diseases linked to pathways in the liver. It has three product candidates in clinical development, including CS-917, a product candidate for the treatment of type 2 diabetes; Pradefovir mesylate, a product candidate for the treatment of hepatitis B that is in phase II clinical trials; and MB07133, a product candidate for the treatment of primary liver cancer that is in a phase I clinical trial. The company has strategic alliances with Sankyo Company, Ltd.; Valeant Pharmaceuticals International; Merck & Co., Inc.; and Sicor, Inc. Metabasis Therapeutics was founded by Paul K. Laikind, Mark D. Erion, and John W. Beck in 1997. The company is headquartered in San Diego, California.
SEATTLE GENETICS INC (SGEN)
Seattle Genetics, Inc. develops monoclonal antibody-based therapeutic products for the treatment of cancer and immunologic diseases. The company's monoclonal antibody-based technologies include genetically engineered monoclonal antibodies, antibody-drug conjugates (ADC), and antibody-directed enzyme prodrug therapy (ADEPT), which are used to develop monoclonal antibodies that can kill target cells on their own, as well as increase the potency of monoclonal antibodies. Its product candidate, SGN-30, is in phase II clinical trials, which is used for the treatment of Hodgkin's disease and systemic anaplastic large cell lymphoma; and SGN-15 has completed a phase II clinical trial for use in the treatment of nonsmall cell lung cancer. The company's SGN-40 is in phase I clinical trials in patients with multiple myeloma. In addition, it has four product candidates in preclinical development: SGN-35, SGN-70, SGN-75, and SGN-17/19. The company is conducting preclinical development tests of SGN-35 for the treatment of hematologic malignancies, such as Hodgkin's disease and some types of nonHodgkin's lymphoma. SGN-75 is an ADC composed of an anti-CD70 monoclonal antibody. The CD70 antigen is expressed on renal cancer, nasopharyngeal carcinoma, and certain hematologic malignancies. SGN-17/19, an ADEPT product candidate, is being developed for the treatment of metastatic melanoma. The company has collaboration agreements with Genentech, Celera Genomics Group, UCB Celltech, Protein Design Labs, PSMA Development Company LLC, CuraGen, and Bayer for its ADC technology; and with Genencor for its ADEPT technology. Seattle Genetics was co-founded in 1997 by H. Perry Fell and Clay B. Siegall. The company is headquartered in Bothell, Washington.
ALTUS PHARMACEUTICALS INC (ALTU)
No description available.
LA JOLLA PHARMACEUTICAL COMPANY (LJPC)
No description available.
BIODELIVERY SCIENCES INTERNATIONAL INC (BDSI)
BioDelivery Sciences International, Inc. operates as a specialty biopharmaceutical company that uses its licensed and patented drug delivery technologies to develop and commercialize new formulations of proven therapeutics targeted at acute treatment opportunities, such as pain, anxiety, nausea and vomiting, and infections. Its lead product under development is Emezine, which is used for treating nausea and vomiting, is in pre-registration stage. The company's licensed drug delivery technologies include the Bioral nanocochleate drug delivery technology, which is designed for a range of applications; and the BEMA drug delivery disc technology, which is applied to the inner cheek membrane. Its Bioral Amphotericin B is an anti-fungal treatment for treating systemic fungal infections. The company's lead BEMA product under development is BEMA Fentanyl, a treatment for cancer pain. BioDelivery Sciences is also developing BEMAT Long Acting Analgesic for treating pain conditions, including post operative and chronic pain due to osteoarthritis, lower back disorders, and rheumatoid arthritis. In addition, the company has a clinical development and license agreement with Clinical Development Capital, LLC relating to its BEMA Fentanyl product. BioDelivery Sciences was incorporated in 1997 and is headquartered in Morrisville, North Carolina.
OXiGENE, Inc. engages in the research and development of products for the treatment of cancer and certain eye diseases. The company focuses on the development of products for application as direct cancer treatment agents, particularly vascular targeting agents (VTAs). It also investigates the use of certain products in the field of ophthalmology, in particular age-related macular degeneration and myopic macular degeneration. The company's technology, Combretastatin, is a family of proprietary small molecule anti-tumor VTAs. OXiGENE's CA4P compound targets the inner areas of the tumor. It is developing OXi4503 that targets blood vessels at the central core of the tumor, and appears to affect the vessels and tumor cells at the periphery. The CA4P is being tested in five human clinical trials in oncology, and one human clinical trial in ophthalmology. It is in Phase I/II combination clinical trial with Carboplatin and Paclitaxel in advanced ovarian cancer. In addition, a Phase II single agent trial in advanced and metastatic anaplastic thyroid carcinoma (ATC), and a Phase I/II combination trial in newly diagnosed ATC. OXiGENE is undertaking a Phase I/II combination trial with radiotherapy in head and neck, lung, and prostate cancers, as well as a Phase Ib combination trial with a monoclonal antibody in colorectal cancer. Its anti-tumor agent, OXi6197, reduces blood flow in newly formed tumor vasculature. The company is conducting Phase II single agent trial to treat a form of thyroid cancer, anaplastic thyroid carcinoma and a Phase II study for ATC to evaluate the mean survival time of patients. It is undertaking a Phase Ib study to evaluate the combination of CA4P with the radiolabeled anti-CEA monoclonal antibody A5B7. Additionally, the company has Phase I/II clinical trial for the nonlife threatening ocular disease, wet age-related macular degeneration. OXiGENE was incorporated in 1988 and is headquartered in Waltham, Massachusetts.
SANGAMO BIOSCIENCES INC (SGMO)
Sangamo Biosciences, Inc. engages in the research, development, and commercialization of DNA binding proteins for the therapeutic regulation and modification of disease-associated genes. The company's gene regulation technology platform is enabled by the engineering of a class of transcription factors, known as zinc finger DNA-binding proteins (ZFPs). The applications of the company's technology include pharmaceutical discovery, development of human therapeutics, and plant agriculture. It has also initiated preclinical animal studies of ZFP therapeutics in congestive heart failure, nerve regeneration, and neuropathic pain; and has research-stage programs in human immunodeficiency virus, sickle cell anemia, X-linked severe combined immunodeficiency, Wiskott Aldrich Syndrome, age-related macular degeneration, and cancer immunotherapy. The company has strategic partnership with Edwards Lifesciences Corporation. Sangamo BioSciences has a research collaboration agreement with Pfizer, Inc. to develop cell lines for enhanced protein production. Sangamo Biosciences was founded in 1995 by Edward Lanphier. The company is headquartered in Richmond, California.
SUNESIS PHARMACEUTICALS INC (SNSS)
No description available.
EntreMed, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics primarily for the treatment of cancer. It develops multimechanism oncology and anti-inflammatory drugs that target disease cells directly and the blood vessels that nourish them. The company's lead drug candidate Panzem (2-methoxyestradiol or 2ME2) is in clinical trials for cancer, as well as in preclinical development for nononcology indications. Panzem is in Phase I and Phase II clinical trials. The company also develops various molecules, including analogs of 2ME2, modulators of fibroblast growth factor-2 activity, tissue factor pathway inhibitor peptides, and proteinase activated receptor-2 antagonists to inhibit tumor growth and angiogenesis activities. The company has a strategic alliance with Allergan to develop and commercialize small molecule angiogenic inhibitors for the treatment and prevention of diseases and conditions of the eye; research collaboration with Affymax, Inc. to identify lead tissue factor pathway inhibitor drug candidates for the treatment of cancer; and a cooperative research and development agreement with the National Cancer Institute to evaluate the role of HIF-1alpha inhibition in the treatment of cancer. EntreMed was incorporated in 1991 and is based in Rockville, Maryland.
VICAL INCORPORATED (VICL)
Vical Incorporated engages in the research and development of biopharmaceutical products for the prevention and treatment of serious or life-threatening diseases. The company focuses on the development of biopharmaceutical product candidates based on its patented deoxyribonucleic acid (DNA) delivery technologies. It develops various DNA-based vaccines and therapeutics for the prevention or treatment of infectious diseases, cancer, and cardiovascular diseases. Vical primarily develops its cancer immunotherapeutics, Allovectin-7 and IL-2/Electroporation, as well as a plasmid DNA vaccine for cytomegalovirus. Allovectin-7, which completed its Phase II clinical trials, is a plasmid/lipid complex containing the DNA sequences encoding HLA-B7 and ß2 microglobulin, which together form a Class I Major Histocompatibility Complex antigen. Allovectin-7 is being developed as a treatment for metastatic melanoma, a form of skin cancer. IL-2/Electroporation program that is in Phase 1 clinical testing is a gene-based, electroporation enhanced delivery of interleukin-2, or IL-2, a potent immunotherapeutic agent, as a treatment for solid tumors, with an initial indication in metastatic melanoma. Vical also develops an anthrax vaccine, which is in Phase 1 clinical testing. The company was incorporated in 1987 and is based in San Diego, California.
CELL THERAPEUTICS INC (CTIC)
Cell Therapeutics, Inc. engages in the discovery, development, acquisition, and commercialization of drugs for the treatment of cancer. The company markets TRISENOX (arsenic trioxide) for the treatment of relapsed or refractory acute promyelocytic leukemia. Cell Therapeutics develops XYOTAX, paclitaxel linked to a polyglutamate polymer, which is used for the potential treatment of nonsmall cell lung cancer and ovarian cancer. It uses a biodegradable protein polymer to deliver the chemotherapy paclitaxel principally to tumor tissue. The company develops pixantrone, which is in clinical trials for the potential treatment of relapsed aggressive nonhodgkin's lymphoma. It operates primarily in the United States and Italy. The company was co-founded by James A. Bianco, Louis A. Bianco, and Jack W. Singer in 1991. Cell Therapeutics is headquartered in Seattle, Washington.
NEOSE TECHNOLOGIES INC (NTEC)
Neose Technologies, Inc., a biopharmaceutical company, engages in the research and development of proprietary drugs primarily therapeutic proteins. The company's products include GlycoPEG-EPO, which stimulates the production of red blood cells for the treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure; and GlycoPEG-GCSF that stimulates the production of neutrophils for the treatment of neutropenia associated with myelosuppressive chemotherapy. Neose Technologies has collaborations with BioGeneriX, Novo Nordisk A/S, and MacroGenics, Inc. for the research and development of its GlycoAdvance and GlycoPEGylation technologies. Neose Technologies was incorporated in 1989 and is headquartered in Horsham, Pennsylvania.
Compugen, Ltd. develops platforms, discovery engines, and related technologies that enable the discovery and analysis of genes and gene-based products, as well as mRNAs and proteins. Its platforms comprise LEADS computational biology platform, which analyzes genomic and expressed sequence data to enable discovery of genes, mRNAs, and proteins; and discovery engines that enable its researchers to identify proteins and mRNAs with predetermined properties for therapeutic and diagnostic development. The company initiates the predictive modeling of alternative splicing, antisense, and the RNA editing that provides the basis for understandings of additional biological phenomena. Compugen has an early stage in-house pipeline consisting of selected therapeutic protein candidates discovered by the company; and additional discoveries that are out-licensed for development. It also focuses on novel splice variants of known and validated therapeutic proteins, as well as novel diagnostic markers. These novel proteins constitute an intellectual property portfolio, which includes novel prostate specific antigens, a novel vascular endothelial growth factor, a splice variant of CD40, and other proteins. The company operates primarily in the United States, Israel, Europe, and the Far East. Compugen has a collaboration agreement with Ortho-Clinical Diagnostics, Inc. for the development and commercialization of immunoassay diagnostic markers. The company was established in 1993 and is headquartered in Tel Aviv, Israel.
PHARMOS CORPORATION (PARS)
Pharmos Corporation, a bio-pharmaceutical company, engages in the discovery and development of drugs to treat neurological and inflammatory disorders. Its proprietary technology platform focuses on the discovery and development of synthetic cannabinoid compounds. The company's lead product candidate, Cannabinor, is a CB2-selective class compound in late-stage preclinical development, which would be used as an analgesic to treat moderate to severe pain of various etiologies. Its neuroprotective drug candidate, dexanabinol, a Phase IIa trial completed product, would be used as a preventive agent against post-surgical cognitive impairment. Pharmos's NanoEmulsion drug delivery system is in clinical-stage development for topical application of analgesic and anti-inflammatory agents. The company also has various other compounds in preclinical studies focusing on pain, multiple sclerosis, rheumatoid arthritis, and other disorders. Pharmos operates in the United States and Israel. The company, formerly known as Pharmatec, Inc., was incorporated in 1982. Pharmos is headquartered in Iselin, New Jersey.
Favrille, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. Its proprietary technology enables it to manufacture active immunotherapy products that are designed to stimulate a patient''s immune system to mount a specific and sustained response to disease. The company's product candidate, FavId, is an active immunotherapy used for the treatment of indolent B-cell nonHodgkin''s lymphoma (NHL) that is based upon genetic information extracted from a patient''s tumor. Favrille is developing a second product candidate, FAV-201, for the treatment of T-cell lymphoma. It also intends to initiate preclinical studies to identify additional product candidates for the treatment of autoimmune diseases, with an initial focus on multiple sclerosis. Favrille was co-founded by Daniel P. Gold and Bob Shopes in 2000. The company is headquartered in San Diego, California.
DENDREON CORPORATION (DNDN)
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of targeted therapies for cancer. Its portfolio of product candidates includes therapeutic vaccines, monoclonal antibodies, and small molecules to treat a range of cancers. The company's lead product candidate, Provenge (sipuleucel-T), is an investigational active cellular immunotherapy in Phase III clinical trials for the treatment of metastatic, androgen independent prostate cancer. In addition, Dendreon completed Phase I clinical trials for Neuvenge (lapuleucel-T), an investigational active cellular immunotherapy for the treatment of breast, ovarian, and other solid tumors. Its preclinical programs include monoclonal antibodies, therapies targeting the trp-p8 pathway and serine protease product candidates for the treatment of cancer. The company has research and development alliances with Genentech, Inc.; Abgenix, Inc.; and Dyax Corp. Dendreon was formed in 1992 and is headquartered in Seattle, Washington.
Cell Genesys, Inc., a biotechnology company, engages in the research, development, and commercialization of biological therapies for patients with cancer. The company develops cell-based cancer vaccines, oncolytic virus therapies, and antiangiogenesis therapies to treat various types of cancer. Its clinical stage cancer programs comprise cell- or viral-based products that have been genetically modified during product development to impart disease-fighting characteristics. The company's clinical-stage programs include GVAX cancer vaccines and oncolytic virus therapies. Cell Genesys' GVAX cancer vaccines program includes Phase 3 clinical trials for prostate cancer and Phase 2 clinical trials for pancreatic cancer and leukemia. The company's oncolytic virus therapies program includes a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer and other types of cancer. It has a strategic alliance with Novartis AG to develop and commercialize oncolytic virus therapies, and has collaboration agreements with Medarex, Inc. and Abgenix, Inc. Cell Genesys was incorporated in 1988 and is headquartered in South San Francisco, California.
CURAGEN CORPORATION (CRGN)
CuraGen Corporation operates as a genomics-based pharmaceutical development company in the United States. The company has various projects of protein, antibody, and small molecule therapeutics in preclinical and clinical development in the therapeutic areas of oncology, inflammatory diseases, and diabetes. Its clinical products include CG53135, a protein therapeutic for the prevention and treatment of oral mucositis in cancer patients; PXD101, a Phase II clinical trail HDAC inhibitor for patients with advanced multiple myeloma; and CR002, a novel fully-human monoclonal antibody to treat kidney inflammation, such as IgA nephropathy. The company's clinical products also include CR011, a fully-human monoclonal antibody-drug conjugate for the treatment of metastatic melanoma; and CT052, an investigational small molecule drug for the management of adult-onset (type 2) diabetes. In addition, CuraGen Corporation, through its 454 Life Sciences Corporation subsidiary, commercializes novel nanoscale instrumentation and technologies for determining the nucleotide sequence of entire genomes. 454 Life Sciences' technology serves various industries, including industrial processes, agriculture, animal health, and biodefense, as well as human health care comprising drug discovery and development, and disease diagnosis. The company has strategic alliances with Abgenix, Inc. to support its antibody projects; Bayer AG to support small molecule projects for diabetes; TopoTarget A/S to support small molecule histone deacetylase inhibitor projects for oncology and inflammatory diseases; and Seattle Genetics, Inc. to support antibody-drug conjugate projects. CuraGen Corporation was founded by Jonathan M. Rothberg. The company was incorporated in 1991 and is headquartered in New Haven, Connecticut.
CYTOKINETICS INCORPORATED (CYTK)
Cytokinetics Incorporated, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule drugs that specifically target the cytoskeleton. Cytoskeleton is a diverse, multi-protein framework that carries out fundamental mechanical activities of cells including mitosis, or the division of genetic material during cell division, intracellular transport, cell movement and contraction, and overall cell organization. The company's focus on the cytoskeleton enables it to develop novel drugs for cancer, cardiovascular, fungal, and other diseases. It has two drug candidates, SB-715992 and SB-743921, which are in the phase-1 and phase-2 clinical trial, and a novel drug candidate for the treatment of congestive heart failure. Cytokinetics has strategic alliances with GlaxoSmithKline and AstraZeneca AB. The company was co-founded by Ronald D. Vale, Lawrence S. B. Goldstein, and James A. Spudich in 1997. Cytokinetics is headquartered in San Francisco, California.
TITAN PHARMACEUTICALS INC (TTP)
Titan Pharmaceuticals, Inc., a biopharmaceutical company, develops proprietary therapeutics for the treatment of central nervous system disorders, cardiovascular disease, bone diseases, and other disorders. It offers Probuphine, Iloperidone, Spheramine, DITPA, and Gallium maltolate. Probuphine is phase III clinical study for the treatment of opiate addiction and chronic pain. Iloperidone is in phase III for the treatment of schizophrenia and related psychotic disorders. Spheramine is in phase IIb for the treatment of advanced Parkinson's disease. DITPA is in phase II for the treatment of congestive heart failure and hyperlipidemia. Gallium maltolate is in phase I for the treatment of bone related diseases and other disorders. Titan Pharmaceuticals was incorporated in 1992 and is based in South San Francisco, California.
ENCYSIVE PHARMACEUTICALS INC (ENCY)
Encysive Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel, synthetic, and small molecule compounds. Its research and development programs are focused on the treatment and prevention of interrelated diseases of the vascular endothelium, the intravascular inflammatory process, and the vascular diseases. The company offers a Food and Drug Administration approved drug called Argatroban for the treatment of heparin-induced thrombocytopenia. Argatroban is marketed by GlaxoSmithKline, PLC. In addition, Encysive Pharmaceuticals completed Phase III development of the endothelin antagonist known as Thelin for pulmonary arterial hypertension. Further, its majority owned affiliate, Revotar Biopharmaceuticals AG, was in Phase II development with the selectin antagonist called bimosiamose in asthma, psoriasis, and atopic dermatitis. Additionally, Encysive Pharmaceuticals has several other research and development programs for a range of cardiovascular and inflammatory diseases. Encysive Pharmaceuticals has collaboration agreements with Mitsubishi Pharma Corporation, Glaxo SmithKline, and Encysive L.P. The company is headquartered in Houston, Texas.
HOLLIS-EDEN PHARMACEUTICALS INC (HEPH)
Hollis-Eden Pharmaceuticals, Inc., a development stage pharmaceutical company, engages in the discovery, development, and commercialization of products, for the treatment of diseases and disorders, in which the body is unable to mount an appropriate immune response. The company's development efforts focus on radiation and chemotherapy induced immune suppression and immune dysregulation caused by infectious diseases, such as HIV, malaria, and tuberculosis. In addition, Hollis-Eden Pharmaceuticals is developing a nonimmune regulating hormone drug candidate for providing protection against DNA mutations from radiation exposure and chemotherapy treatment. The company was founded in 1992. It was formerly known as Initial Acquisition Corp and changed its name to Hollis-Eden Pharmaceuticals, Inc. in 1997. Hollis-Eden Pharmaceuticals is headquartered in San Diego, California.
EXACT SCIENCES CORPORATION (EXAS)
EXACT Sciences Corporation utilizes applied genomics to develop screening technologies for use in the detection of cancer. Certain of its technologies are offered in a commercial testing service, PreGen-Plus, developed by Laboratory Corporation of America Holdings. PreGen-Plus is a non-invasive stool-based DNA testing service for the detection of colorectal cancer in the average-risk population. EXACT Sciences was founded in 1995 and is headquartered in Marlborough, Massachusetts.
ViaCell, Inc. operates as a biotechnology company that focuses on enabling the use of human cells as medicine. The company is developing a pipeline of proprietary stem cell product candidates intended to address cancer, cardiac disease, and diabetes. CB001, its lead cord blood derived stem cell therapy product, is being developed for hematopoietic stem cell transplantation in patients affected by a variety of cancers. In addition to its therapeutic development programs, ViaCell's reproductive health business unit commercializes ViaCord, a product that offers expecting families the option of preserving their baby's umbilical cord blood. It is also developing ViaCyte, its investigational product intended to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell was incorporated as t.Breeders, Inc. in 1994 and changed its name to ViaCell, Inc. in 2000. The company is headquartered in Cambridge, Massachusetts with a processing and storage facility in Kentucky, as well as additional research and development operations in Singapore.
ADVENTRX PHARMACEUTICALS INC (ANX)
ADVENTRX Pharmaceuticals, Inc. operates as a biopharmaceutical research and development company. The company focuses on new technologies for anticancer and antiviral treatments, which address drug metabolism, toxicity, bioavailability, or resistance problems. Its lead product includes CoFactor, a folate-based biomodulator drug, which is used for the treatment of metastatic GI and breast cancers, metastatic colorectal cancer, and metastatic pancreatic cancer. CoFactor is tested with 5-FU in a U.S. based Phase II and an EU-based Phase IIb clinical trial as a first line treatment of metastatic colorectal cancer. In addition, CoFactor received clearance under a special protocol assessment from the U.S. FDA for a Phase III pivotal clinical trial for metastatic colorectal cancer. ADVENTRX Pharmaceuticals also has an exclusive license from the University of Southern California to develop and commercialize CoFactor. The company, formerly known as Biokeys Pharmaceuticals, Inc., was organized in 1995 and changed its name to ADVENTRX Pharmaceuticals, Inc. in 2003. ADVENTRX Pharmaceuticals is based in San Diego, California.
MARTEK BIOSCIENCES CORPORATION (MATK)
Martek Biosciences Corporation engages in the development, manufacture, and sale of products derived from microalgae and other microbes primarily in the United States. Its products include nutritional oils used in infant formula, nutritional supplements, and food fortification ingredients, and fluorescent markers for diagnostics and rapid miniaturized screening. The company's nutritional oils consist of fatty acid components, such as docosahexaenoic acid (DHA) and arachidonic acid (ARA). DHA and ARA help in developing the eyes and central nervous systems of newborns, and DHA helps in promoting adult mental and cardiovascular health. It develops fluorescent detection products from microalgae that connect fluorescent algal proteins to antibodies. These products and technologies enable researchers in drug discovery and diagnostics. Fluorescent detection products include Phycobiliproteins, which are classical direct fluorescent detection dyes and SensiLight dyes that are used to match the sensitivity of chemiluminescent methods. Martek Biosciences markets and sells its nutritional oils primarily to the infant formula and natural products industries. The company has a collaborative agreement with SemBioSys Genetics, Inc., a Canadian biotechnology company, to co-develop plant-based DHA products. Martek Biosciences was founded by Radmer in 1985. The company is based in Columbia, Maryland.
Immunomedics, Inc. engages in the development, manufacture, and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer, autoimmune, and other diseases. The company offers its CEA-Scan, a diagnostic imaging agent used for the detection of colorectal cancers, in the United States and Canada, as well as in Europe. It offers its LeukoScan, a diagnostic product used for the detection of bone infections, in Europe and Australia. Immunomedics' therapeutic product candidates primarily comprised epratuzumab, which completed certain Phase II clinical trials for the treatment of nonHodgkin's lymphoma, as well as labetuzumab, which was in Phase I/II clinical trials for the treatment of certain solid tumors and hematologic malignancies, as of June 30, 2004. The company was founded by David M. Goldenberg. Immunomedics was incorporated in 1982 and is headquartered in Morris Plains, New Jersey.
BIOCRYST PHARMACEUTICALS INC (BCRX)
BioCryst Pharmaceuticals, Inc. engages in the design, optimization, and development of small-molecule drugs that treat cancer, cardiovascular, and autoimmune diseases, as well as viral infections. The company focuses on building potent, selective inhibitors of enzymes associated with targeted diseases. BioCryst Pharmaceuticals integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to use structure-based drug design to discover and develop small molecule pharmaceuticals. Its lead product candidate, Fodosine, is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). The drug is in a Phase IIa trial for patients with T-cell leukemia and in a Phase I trial with an oral formulation in cutaneous T-cell lymphoma. The company's pipeline products include PNP Inhibitor (BCX-4208), Hepatitis C Polymerase Inhibitors, and Tissue Factor/Factor VIIa Inhibitors. PNP Inhibitor (BCX-4208), a phase I clinical trial product, is intended for the treatment of T-cell mediated autoimmune diseases, including psoriasis. Hepatitis C Polymerase Inhibitor, a product under lead optimization stage, is intended for the treatment of viral infections. Tissue Factor/Factor VIIa, a product under lead optimization stage, is intended for the treatment of acute coronary syndromes and complications associated with cardiovascular procedures. The company has strategic agreement with Sunol Molecular Corp. to conduct research and supply of protein targets for drug design for its cardiovascular program. BioCryst Pharmaceuticals was co-founded in 1986 by Charles E. Bugg, John A. Montgomery, and William M. Spencer, III. The company is headquartered in Birmingham, Alabama.
No description available.
KOSAN BIOSCIENCES INCORPORATED (KOSN)
Kosan Biosciences Incorporated, a biotechnology company, develops drug candidates from a class of natural product compounds known as polyketides. The company has collaboration agreements with Hoffmann-La Roche, Inc. and F. Hoffmann-La Roche, Ltd. to co-develop and commercialize KOS-862 and KOS-1584 product candidates that are epothilones for the treatment of cancer. KOS-862 is in Phase II and Phase Ib clinical trials, and KOS-1584 is in a Phase I clinical trial. In addition, Kosan Biosciences develops 17-AAG and other analogs of geldanamycin; and KOS-1022, a water-soluble and orally-available analog of geldanamycin for the treatment of cancer. 17-AAG is in Phase II and Phase Ib combination clinical trials, as well as KOS-1022 is in Phase I clinical trials. The company was co-founded by Daniel V. Santi and Chaitan S. Khosla. Kosan Biosciences was founded in 1995 and is based in Hayward, California.
GENITOPE CORPORATION (GTOP)
Genitope Corporation, a biotechnology company, engages in the research and development of novel immunotherapies for the treatment of cancer. Its Immunotherapies are treatments that utilize the immune system to combat diseases. The company's primary product, MyVax personalized immunotherapy is a patient-specific active immunotherapy that is based on the unique genetic makeup of a patient's tumor and is designed to activate a patient's immune system to identify and attack cancer cells. As of March31, 2005, MyVax was in a Phase III clinical trial and additional Phase II clinical trials for the treatment of B-cell nonHodgkin's lymphoma, or B-cell NHL. The company operates in the United States and Canada. Genitope was founded by Dan W. Denney, Jr. in 1996. The company is based in Redwood City, California.
PDL BioPharma, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for treatment of inflammation and autoimmune diseases, acute cardiac conditions, and cancer. It markets and distributes various biopharmaceutical products, including Cardene I.V. for the short-term treatment of hypertension; Retavase, a fibrinolytic agent for the management of acute myocardial infarction or heart attack in adults for the improvement of ventricular function; and IV Busulfex that is used as a conditioning agent in blood or marrow transplantation in chronic myelogenous leukemia. The company also develops various other products, such as Daclizumab for the treatment of asthma and multiple Sclerosis; Ularitide to treat decompensated congestive heart failure; Terlipressin for the treatment of Type 1 hepatorenal syndrome; HuZAF to treat crohn's disease; Nuvion for the treatment of severe steroid-refractory ulcerative colitis; and M200 to treat solid tumors. PDL BioPharma markets its biopharmaceutical products in the United States and Canada through its hospital sales force. The company was founded by Laurence Jay Korn in 1986. It was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in June 2005. PDL BioPharma is headquartered in Fremont, California.
Biomira, Inc., a biotechnology company, engages in the research and development of synthetic vaccines and novel strategies for cancer immunotherapy. The company's product candidates include BLP25 liposome vaccine, a synthetic Mucin 1 peptide vaccine, which is in Phase IIb trial; and Theratope, a carbohydrate vaccine, which is in Phase III trial. It also developed a synthetic MUC 1-based liposomal glycolipopeptide cancer vaccine, BGLP40 liposome vaccine, which in late pre-clinical development, for use in several cancer indications, including ovarian and breast cancer. The company has collaboration agreement with Merck KGaA of Darmstadt for global product development, licensing, and co promotion of BLP25 liposome. Biomira was incorporated in 1985 and is headquartered in Edmonton, Canada.
BARRIER THERAPEUTICS INC (BTRX)
Barrier Therapeutics, Inc. engages in the discovery, development, and commercialization of pharmaceutical products in the field of dermatology. The company markets Solage in the U.S. for the treatment of solar lentigines, a common condition also known as age spots or liver spots, and for the broader indication, including related hyperpigmented lesions in Canada. It has eight product candidates in various stages of clinical development, which include Zimycan, Sebazole, Hyphanox, Liarozole, Rambazole, Azoline, and Hivenyl. Zimycan is an ointment for the treatment of infants with diaper dermatitis complicated by an inflammatory disease characterized by diaper rash complicated with an infection by a yeast called Candida; Sebazole is a gel for the treatment of seborrheic dermatitis; Hyphanox, which is in phase III clinical trails, is an oral therapeutic for the treatment of fungal infections; and Liarozole is an oral therapeutic for the treatment of the group of conditions known as congenital ichthyosis, a genetic disease characterized by dryness and scaling of the skin. It develops Rambazole as an oral formulation for the treatment of psoriasis and severe acne, and a topical formulation for dermatological indications, including common forms of acne and mild to moderate psoriasis; Azoline as an oral treatment for skin and mucosal fungal infections; and Hivenyl as an oral treatment for allergic reactions of the skin. In addition, the company engages in the reformulation of Atopik, a PDE4 inhibitor, as a topical treatment for eczema, as well as has rights to two products, ketanserin and oxatomide, that are marketed by third parties. Ketanserin is a topical serotonin 2 antagonist used for the treatment of chronic skin ulcers and Oxatomide is a topical histamine, serotonin, and leukotriene antagonist used for the prevention and treatment of allergies. Barrier Therapeutics was founded in 2001 by Geert Cauwenbergh. The company is headquartered in Princeton, New Jersey.
Dyax Corp. engages in the discovery, development, and commercialization of antibodies, small proteins, and peptides as therapeutic products, particularly in the areas of inflammation and oncology. As of December 31, 2004, the company had two product candidates in, or entering into, Phase II clinical trials for three indications. DX-88 is being studied for the treatment of both hereditary angioedema and for the prevention of blood loss, and other systemic inflammatory responses in on-pump open-heart surgery and other surgical indications, and DX-890 is being studied for the treatment of cystic fibrosis. In collaboration with Genzyme Corporation, Dyax is conducting an open-label, repeat dose Phase II clinical trial of DX-88. It has completed a Phase I/II study of DX-88 in the United States in patients undergoing coronary artery bypass grafting surgery. The company in collaboration with Debiopharm S.A. for DX-890 has completed two Phase IIa clinical trials, one in adults and one in pediatric cystic fibrosis patients. It uses its proprietary, patented technology, known as phage display, to identify a range of compounds consisting of monoclonal antibodies, small proteins, and peptides with the potential for the treatment of various diseases. The company has 12 discovery programs underway: 7 in oncology, which are focused on the discovery and development of therapies that fight cancer; 4 focused on targets that are believed to be mediators of inflammation; and 1 program focused on an infectious disease target. The company has collaboration agreements with AstraZeneca AB; Dendreon Corporation; Baxter Healthcare S.A.; Biogen Idec, Inc.; Inhibitex, Inc.; Debiopharm S.A.; and Syntonix Pharmaceuticals, Inc. Dyax was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
COMBINATORX INCORPORATED (CRXX)
No description available.
ADVANCED LIFE SCIENCES HOLDINGS INC (ADLS)
No description available.
Orthologic Corp., a drug development company, engages in healing musculoskeletal, orthopedic, dermal, and cardiovascular tissues through biopharmaceutical approaches. The company develops Chrysalin, or TP508, a 23-amino acid synthetic peptide that stimulates body's natural healing processes. It also develops Chrysalin-based product candidates, which are in preclinical trials and are used for fractures, healing diabetic foot ulcers, spinal instability, cartilage defect repair, cardiovascular repair, dental bone repair, and ligament and tendon repair. In addition, the company's product development pipeline includes Chrysalin-based product candidates for spinal fusion, dental bone formation, and myocardial revascularization. Orthologic Corp. was incorporated in 1987. It was formerly known as IatroMed, Inc. and changed its name to Orthologic Corp. in 1991. The company is headquartered in Tempe, Arizona.
PRAECIS PHARMACEUTICALS INCORPORATED (PRCS)
PRAECIS PHARMACEUTICALS INCORPORATED, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of human diseases. It provides Plenaxis, a gonadotropin releasing hormone antagonist approved for use in prostate cancer patients as a depot formulation in the United States, as well as Apan for the treatment of Alzheimer's disease. The company also offers a MetAP-2 inhibitor, PPI-2458, which is in clinical development for nonHodgkin's lymphoma and solid tumors; and a drug discovery technology, Direct Select that enables the generation and use of ultra-large libraries for the discovery of orally active compounds for drug development. PRAECIS PHARMACEUTICALS' research and development pipeline includes clinical programs in Alzheimer's disease, nonHodgkin's lymphoma, and androgen-independent prostate cancer, as well as certain early stage discovery projects. It sells its products directly to pharmaceutical distributors and pharmacies. The company was founded in 1993 by Malcolm L. Gefter. It was formerly known as Pharmaceutical Peptides, Inc. and changed its name to PRAECIS PHARMACEUTICALS INCORPORATED in 1997. PRAECIS PHARMACEUTICALS is headquartered in Waltham, Massachusetts.
Cerus Corporation develops products for cancer, infectious disease, and blood safety. It develops cancer immunotherapies based on its Listeria vaccine platform combined with disease antigens. The company is also developing the INTERCEPT Blood System, which is based on the company's Helinx technology for controlling biological replication. The INTERCEPT Blood System is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, other pathogens, and white blood cells. This system targets and inactivates blood-borne pathogens, such as HIV and hepatitis B and C, as well as harmful white blood cells, while leaving the therapeutic properties of the blood components intact. Cerus is also developing a proprietary vaccine platform to stimulate the immune system to target and attack cancer cells and infectious diseases. The company has collaboration agreements with Baxter Healthcare Corporation and BioOne Corporation for the joint development of the INTERCEPT Blood System for platelets and plasma; and with MedImmune, Inc. to co-develop a therapeutic vaccine designed to treat cancers of the breast, prostate, and colon, as well as metastatic melanomas. Cerus was incorporated in 1991 and is based in Concord, California.
ONYX PHARMACEUTICALS INC (ONXX)
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of small molecule drugs for the treatment of cancer. Its primary product includes sorafenib, a Phase III orally available signal transduction inhibitor, inhibits proliferation of cancer cells and angiogenesis. In addition, sorafenib inhibits VEGFR-2 and PDGFR-ß, two proteins involved in angiogenesis, and other proteins that might be implicated in cancer. The company also develops PD 332991, a Phase I clinical trial product, a small molecule cell cycle inhibitor targeting a cyclin-dependent kinase. Onyx Pharmaceuticals has collaboration agreement with Bayer Pharmaceuticals Corporation to discover, develop, and market compounds that inhibit the function, or modulate the activity, of the RAS signaling pathway to treat cancer and other diseases. The company was established in 1992 and is headquartered in Emeryville, California.
Bioenvision, Inc, a biopharmaceutical company, develops cancer therapeutics in the United States and the United Kingdom. Its products include clofarabine, a purine nucleoside analog, for the treatment of acute and chronic leukemias, lymphomas, and solid tumors; and Modrenal, for the treatment of post-menopausal advanced breast cancer following relapse to initial hormone therapy. The company also offers an animal health product, Vetoryl, for the treatment of Cushing's disease in dogs. In addition, it is developing Virostat for hepatitis C; and Velostan, a cytostatic drug, for bladder cancer, as well as a gene therapy technology platform to treat hypoalbuminemia and liver failure. The company sells its products to wholesale distributors and directly to hospitals, clinics, and retail pharmacies. It has co-development partnership with Genzyme Corporation. Bioenvision was founded by Christopher B. Wood. The company was incorporated as Express Finance, Inc. in 1996. It changed its name to Ascot Group, Inc. in 1998 and to Bioenvision, Inc. in 1999. Bioenvision is headquartered in New York City.
ALFACELL CORPORATION (ACEL)
Alfacell Corporation, a development stage company, operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of a class of therapeutic drugs based on its ribonuclease technology for the treatment of cancer, infectious diseases, and other life-threatening conditions. The company focuses primarily on the development of ribonucleases, a family of proteins isolated from the leopard frog. Its product ONCONASE, an amphibian ribonuclease, is in Phase III trial. ONCONASE affects primarily exponentially growing malignant cells. Alfacell also discovered amphinases, a series of proteins, which are bioactive and effective on living cells and organisms, and have both anti-cancer and anti-viral activity. The company was founded by Kuslima Shogen. Alfacell was incorporated in Delaware in 1981 and is based in Bloomfield, New Jersey.
NEUROBIOLOGICAL TECHNOLOGIES INC (NTII)
Neurobiological Technologies, Inc., a biotechnology company, engages in the acquisition and development of central nervous system related drug candidates. It focuses on therapies for neurological conditions that occur in connection with dementia, alzheimer's disease, ischemic stroke, neuropathic pain, and brain cancer. Neurobiological Technologies offers Memantine an orally dosed compound used for the treatment of alzheimer's disease and neuropathic pain in the United States and Europe. The company also develops Viprinex, which is a late-stage reperfusion therapy for use in the treatment of acute ischemic stroke. Neurobiological Technologies has a strategic research and marketing cooperation agreement with Merz Pharmaceuticals GmbH and Children's Medical Center Corporation to further the clinical development and commercialization of Memantine. The company was founded by Enoch Callaway and John B. Stuppin in 1987. Neurobiological Technologies is based in Emeryville, California.
NPS PHARMACEUTICALS INC (NPSP)
NPS Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of small molecules and recombinant proteins. The company's product candidates are used primarily for the treatment of bone and mineral disorders, gastrointestinal disorders, and central nervous system disorders. NPS's products include PREOS, Calcilytic Compounds, Cinacalcet HCl, Teduglutide, mGluR5 Antagonists, Isovaleramide, Delucemine, Metabotropic Glutamate Receptors, and Glycine Reuptake Inhibitors. The PREOS and Calcilytic Compounds are in phase III and I stage respectively, which are used for the treatment of osteoporosis. The Cinacalcet HCl is in phase II stage, which is used for Hyperparathyroidism. The Teduglutide is in phase II stage and is used for short bowel syndrome or crohn's disease. The mGluR5 Antagonists is in the preclinical stage, which is for gastroesophageal reflux disease. The Isovaleramide is in phase II stage and is used for migraine. The Delucemine is in phase I stage that is used for depression. The Metabotropic Glutamate Receptors is in preclinical stage, which is used for psychiatric and neurologic disorders and pain. The Glycine Reuptake Inhibitors is in preclinical stage that is used for schizophrenia and dementia. The company has collaborative research, development, or license agreements with Amgen, Inc.; AstraZeneca AB; Janssen Pharmaceutical N.V; GlaxoSmithKline; Kirin Brewery, Ltd.; and Nycomed Danmark ApS. The company was founded in 1986 and is headquartered in Salt Lake City, Utah.
ARIAD PHARMACEUTICALS INC (ARIA)
ARIAD Pharmaceuticals, Inc. engages in the discovery and development of medicines to treat cancer by regulating cell signaling with small molecules. Its lead cancer product candidate, AP23573, is an mTOR inhibitor to treat solid tumors and hematologic malignancies. AP23573 is in multiple Phase II and Ib clinical trials as a single agent in patients with hematologic malignancies and solid tumors. Two multicenter Phase Ib studies with AP23573 in combination with other anti-cancer therapies, which are underway in Europe, focus primarily on patients with breast, ovarian, non-small-cell lung, and prostate cancers, as well as certain sarcomas. ARIAD also has an exclusive license to technology and patents related to certain NF-kB treatment methods, as well as the discovery, development, and use of drugs to regulate NF-kB cell-signaling activity, which might be useful in treating certain diseases. In addition, the company has a partnership with Medinol, Ltd., a cardiovascular medical device company, to develop and commercialize stents and other medical devices to deliver AP23573 to prevent reblockage of injured vessels following stent-assisted angioplasty, a common nonsurgical procedure for dilating or opening narrowed arteries. ARIAD was founded in 1991 by Harvey J. Berger and is headquartered in Cambridge, Massachusetts.
Nanogen, Inc. provides human molecular diagnostic products to research, clinical laboratory, and point-of-care markets in North America, Europe and Asia. Its products include instruments, consumables, electronic microarrays, analyte specific reagents, and point-of-care diagnostic tests. The company offers NanoChip Molecular Biology Workstation, an automated, multipurpose instrument primarily used for DNA-based analyses; and the NanoChip Cartridge, which provides a tool for the identification and analysis of biological test samples containing charged molecules. It also provides various analyte specific reagents for the detection of gene mutations associated with diseases, such as cystic fibrosis, Alzheimer's disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia, and Canavan disease. In addition, it offers general purpose reagents and accessories that are used to facilitate assay and protocol development and validation on the NanoChip Platform. The company's microarray instrument platform includes electronic microarray system for multiplexed mutation detection. Nanogen also provides technical support and field applications assistance to service and support its customers. It sells its products to research and molecular diagnostics laboratories. The company also provides contract research services. Nanogen was incorporated in 1991 and is based in San Diego, California.
Trimeris, Inc. engages in the identification, development, and commercialization of therapeutic agents that block viral infection by inhibiting viral fusion with host cells. Its principal drug candidate, Fuzeon, is a human immunodeficiency virus (HIV) fusion inhibitor approved in the United States, Canada, European Union, and other countries for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The company has a collaboration agreement with F. Hoffmann-La Roche, Ltd. to develop and market Fuzeon and T-1249, a replacement compound. Trimeris was founded by Dani Bolognesi and Tom Matthews in 1993 and is based in Morrisville, North Carolina.
DISCOVERY LABORATORIES INC (DSCO)
Discovery Laboratories, Inc., a biopharmaceutical company, develops Surfactant Replacement Therapies for respiratory diseases. The company offers Surfaxin, a protein B-based agent, for the prevention of respiratory distress syndrome in premature infants. Discovery Laboratories provides Surfaxin, which is in Phase 2 clinical trials, for bronchopulmonary dysplasia in premature infants, neonatal respiratory disorders in premature infants, and prophylactic/early treatment of meconium aspiration syndrome in full-term infants. It also offers its products for the treatment of acute respiratory distress syndrome in adults in the intensive care unit, as well as a Phase 1b trial of its lung surfactant delivered as an inhaled aerosol for patients who suffer from asthma. In addition, the company evaluating the development of aerosolized formulations of its SRT to prevent or treat acute lung injury, COPD, rhinitis, sinusitis, sleep apnea, and otitis media. It has a strategic alliance with Quintiles Transnational Corp.; PharmaBio Development, Inc.; Chrysalis Technologies; and Laboratorios del Dr. Esteve S.A. The company is headquartered in Warrington, Pennsylvania.
ImmunoGen, Inc. engages in the discovery and development of therapeutic monoclonal antibodies and treatments in the field of oncology in the United States and the United Kingdom. It develops novel, targeted therapeutics using its tumor-activated prodrug (TAP) technology, which uses monoclonal antibodies to deliver potent cell-killing agents. The company's two leading product candidates include huN901-DM1 and huC242-DM4, which are in clinical testing stage. Its huN901-DM1 product candidate consists of the huN901 antibody, which binds to the CD56 antigen, a cytotoxic agent. The company's second clinical TAP product candidate, huC242-DM4, consists of the humanized C242 monoclonal antibody with its cytotoxic agent attached and is in development for the treatment of colorectal, pancreatic, and other cancers. ImmunoGen also licenses its TAP technology to other biotechnology and pharmaceutical companies. ImmunoGen has collaborative partnerships with sanofi-aventis, Biogen Idec, Inc.; Boehringer Ingelheim International GmbH; Centocor, Inc.; Millennium Pharmaceuticals, Inc.; Abgenix, Inc.; Genentech, Inc.; and GlaxoSmithKline plc. The company was organized in 1981 and is headquartered in Cambridge, Massachusetts.
NEUROCRINE BIOSCIENCES INC (NBIX)
Neurocrine Biosciences, Inc. engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. Its product candidates address various pharmaceutical markets, including insomnia, anxiety, depression, various female and male health disorders, multiple sclerosis, diabetes, and other neurological and endocrine related diseases and disorders. Neurocrine has 17 programs in various stages of research and development. Its lead clinical development program, indiplon, for the treatment of insomnia, partnered with Pfizer, Inc., is in Phase III clinical development. The company completed three Phase I single and multiple dose trials with Gonadotropin-releasing Hormone, GnRH, for the treatment of women's health disorders. It also has two Altered Peptide Ligand products in Phase II clinical development, NBI-5788 for multiple sclerosis and NBI-6024 for Type I Diabetes. Neurocrine initiated a Phase I clinical trial with its proprietary compound, urocortin 2 for treating mild to moderate congestive heart disease. The company's CRF program, partnered with GlaxoSmithKline, is developing multiple compounds that are in various stages of research and preclinical development. It also has strategic alliances with Almirall Prodesfarma, S.A.; Wyeth Holdings Corporation; and Eli Lilly and Company. The company was incorporated in 1992 and is headquartered in San Diego, California.
CYTORI THERAPEUTICS INC (CYTX)
No description available.
PANACOS PHARMACEUTICALS INC (PANC)
No description available.
No description available.
Novogen Limited, a pharmaceutical company, engages in the discovery, development, manufacture, and marketing of products based on the isoflavoniod technology. Its product development program comprises a novel range of pharmaceuticals based on phenolic compounds in humans, and dietary supplements based on plant compounds known as isoflavones. The company's products include Promensil, which provides natural relief from the symptoms of menopause, such as hot flushes and night sweats; Trinovin, which maintains normal prostate and urinary function, health and quality of life in men; and Rimostil that maintains bone and cholesterol health, and also to promote health and well-being in women after menopause. In addition, Novogen develops phenoxodiol, which is in phase II clinical trials for the treatment of prostate cancer, ovarian cancer, renal cancer, and squamous cell carcinomas of the cervix, vagina, and vulva. It is also developing NV-04, a cardiovascular drug candidate; and NV-07, an anti-inflammatory drug candidate. The company sells its products through its distributors and other third parties in Australia, New Zealand, the United States, Canada, and certain European countries. Novogen was founded by Graham E. Kelly in 1994. It was formerly known as Norvet Limited. The company is headquartered in North Ryde, Australia.
GTC BIOTHERAPEUTICS INC (GTCB)
GTC Biotherapeutics, Inc. engages in the development and production, of human therapeutic proteins. It focuses on recombinant forms of proteins derived from human blood plasma by the use of transgenic technology. The company's primary product candidate, ATryn, a recombinant form of human antithrombin, is undergoing review for market authorization in Europe. It also develops rhA, a recombinant human albumin; rhAAT, a recombinant form of human alpha-1 antitrypsin; a malaria vaccine; and an agonistic antibody. GTC Biotherapeutics has a collaboration agreement with LEO Pharma A/S to develop and market ATryn for markets in Europe, the Middle East, and Canada. The company is headquartered in Framingham, Massachusetts.
BIOSANTE PHARMACEUTICALS INC (BPA)
BioSante Pharmaceuticals, Inc., a development stage biopharmaceutical company, develops a pipeline of hormone therapy products to treat men and women. Its hormone therapy products address various symptoms, such as impotence, lack of sex drive, muscle weakness, and osteoporosis in men; and menopausal symptoms, including hot flashes, vaginal atrophy, decreased libido, and osteoporosis in women. The company's products include gel formulations of testosterone, estradiol, a combination of estradiol and testosterone, and a combination of estradiol and progestogen. BioSante also develops various hormone therapy gel products, such as Bio-E-Gel, a transdermal bioidentical estrogen gel for the treatment of menopausal symptoms in women; LibiGel, a transdermal bioidentical testosterone gel for the treatment of female sexual dysfunction (FSD); Bio-E/P-Gel, a transdermal combination gel of bioidentical estrogen and a progestogen for the treatment of menopausal symptoms in women; LibiGel-E/T, a transdermal combination gel of bioidentical estrogen and bioidentical testosterone for the treatment of FSD in menopausal women; Bio-T-Gel, a transdermal bioidentical testosterone gel for the treatment of hypogonadism or testosterone deficiency in men. In addition, it engages in the development of calcium phosphate nanotechnology for vaccines, including biodefense vaccines for toxins, such as anthrax and ricin, and drug delivery systems. The company, formerly known as Ben-Abraham Technologies, Inc., was founded by Avi Ben-Abraham in 1996 and changed its name to BioSante Pharmaceuticals, Inc. in 1999. BioSante is headquartered in Lincolnshire, Illinois.
LIPID SCIENCES INCORPORATED (LIPD)
Lipid Sciences, Inc., a development-stage biotechnology company, engages in the research and development of products and processes to treat medical indications, such as cardiovascular disease and viral infections, in which lipids or fat components play a key role. Its technologies are based on a patented process that selectively removes lipids, such as cholesterol from targeted lipoproteins or viruses circulating in blood plasma without disrupting the nontargeted plasma proteins function. The company focuses on applications of delipidation in two primary areas, including cardiovascular disease using its high-density lipoproteins (HDL) therapy platform, as well as viral infections using its viral immunotherapy platform. The HDL therapy platform focuses on developing treatments for the reversal of atherosclerosis, which is the primary cause of heart attacks, stroke, and peripheral vascular disease. The viral immunotherapy platform is focused on treatments for people suffering from conditions caused by lipid-enveloped viruses, such as human immunodeficiency virus, hepatitis B and C, the severe acute respiratory syndrome coronavirus, West Nile, and influenza. Lipid Sciences is headquartered in Pleasanton, California.
ACADIA PHARMACEUTICALS INC (ACAD)
ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company has four drug programs in clinical development and in preclinical and discovery stages. Its three clinical programs are ACP-103 for treatment-induced dysfunctions in Parkinson's disease, which is in phase II clinical trails; and ACP-103 and ACP-104, for the treatment of schizophrenia. In addition, the company has neuropathic pain program in Phase I clinical trials and a glaucoma program in preclinical development in collaboration with Allergan, Inc. ACADIA Pharmaceuticals was founded by Mark R. Brann. The company was incorporated as Receptor Technologies, Inc. in 1993 and is headquartered in San Diego, California.
SGX PHARMACEUTICALS INC (SGXP)
No description available.
IDENIX PHARMACEUTICALS INC (IDIX)
Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of human viral and other infectious diseases. It primarily focuses on the treatment of infections caused by hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). The company's HBV product candidates include telbivudine for the treatment of an inflammatory liver disease associated with chronic HBV infection; and valtorcitabine, which is in phase IIb clinical trial. Idenix also develops valopicitabine or NM283 for the treatment of HCV, as well as a product candidate from the class of compounds known as nonnucleoside reverse transcriptase inhibitors for the treatment of HIV. Its Telbivudine product candidate is in phase III clinical trial, and valopicitabine or NM283 product candidate is in phase IIb clinical trial. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts. Idenix Pharmaceuticals, Inc. is a subsidiary of Novartis Pharma AG.
StemCells, Inc., a biotechnology company, engages in the discovery, development, and commercialization of stem cell-based therapies to treat diseases of the nervous system, liver, and pancreas. It develops therapies that use stem and progenitor cells to treat human diseases and injuries, such as neurodegenerative diseases, including Batten's, Parkinson's, and Alzheimer's diseases, and other metabolic genetic disorders. The company also develops its products for demyelinating disorders, including spinal cord injuries, stroke, hepatitis, chronic liver failure, and diabetes; and multiple sclerosis. StemCells is headquartered in Palo Alto, California.
Tercica, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve endocrine health. Its first product, Increlex or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved for the long-term treatment of severe Primary IGF-1 deficiency, or Primary IGFD. The company is conducting a Phase IIIb clinical study to evaluate the safety and efficacy of Increlex in children with Primary IGFD. Tercica licensed the rights of Genentech, Inc. to develop, manufacture, and commercialize rhIGF-1 products for a range of indications worldwide. The company was founded in 2000 and is based in Brisbane, California.
VION PHARMACEUTICALS INC (VION)
Vion Pharmaceuticals, Inc., a development stage company, engages in the development of therapeutics for the treatment of cancer. The company has two small molecule anticancer agents, including CLORETAZINETM (VNP40101M) and Triapine, in clinical development; and other small molecules and a drug delivery system, including KS119W and heterocyclic hydrazones in preclinical development. Its lead product candidate CLORETAZINETM (VNP40101M), which is in Phase II single agent trial, is a sulfonylhydrazine alkylating agent for the treatment of relapsed acute myelogenous leukemia. Triapine is a small molecule that inhibits the enzyme ribonucleotide reductase, and prevents the replication of tumor cells by blocking a critical step in DNA synthesis. Triapine is in Phase II combination trial with gemcitabine in pancreatic cancer. KS119 is an additional cytotoxic (cell-damaging) compound from the sulfonylhydrazine class. Heterocyclic hydrazones are anticancer compounds that have demonstrated potent antitumor effects. It also has one product development program, TAPET (Tumor Amplified Protein Expression Therapy), a drug delivery system using modified Salmonella bacteria, which is designed to deliver anticancer agents directly to solid tumors. Vion Pharmaceuticals has a collaboration agreement with the National Cancer Institute for the clinical development of Triapine. The company was incorporated in 1992 and was formerly known as OncoRx, Inc. It changed its name to Vion Pharmaceuticals, Inc. in 1996. Vion Pharmaceuticals is based in New Haven, Connecticut.
ANADYS PHARMACEUTICALS INC (ANDS)
Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing small molecule medicines for the treatment of hepatitis C virus (HCV), hepatitis B virus (HBV), and certain bacterial infections. The company's primary clinical development programs include ANA975, an oral prodrug of isatoribine for the treatment of HCV and HBV, and ANA380 for the treatment of HBV. ANA975, which is in phase I clinical trails, is a proprietary chemical entity that is administered orally and then is converted into the active compound, resulting in isatoribine in the bloodstream. ANA380 is in phase II clinical trails in patients with lamivudine-resistant, or lamR, hepatitis B virus. The company also has discovery programs exploring the use of oral prodrugs of TLR-7 agonists and direct antiviral discovery efforts focused on structural-based drug design. In addition, it develops a class of molecules that act against certain bacterial infections, including hospital-based infections, by inhibiting ribosomal function, which is the ability to synthesize new proteins. Anadys Pharmaceuticals has collaborative agreements with Amgen, Inc. and Daiichi Pharmaceutical Co. Ltd. to discover compounds against therapeutic targets of Amgen and Daiichi; and with Aphoenix, Inc. to discover and advance compounds against Aphoenix targets for multiple therapeutic indications. The company was incorporated in 1992 under the name ScripTech Pharmaceuticals, Inc. It changed its name to Scriptgen Pharmaceuticals, Inc. in 1994 and to Anadys Pharmaceuticals, Inc. in 2000. Anadys Pharmaceuticals is headquartered in San Diego, California.
SENESCO TECHNOLOGIES INC (SNT)
Senesco Technologies, Inc. engages in the research and development of genetic technologies for commercial agriculture.The company develops technology for the identification and characterization of specific genes that are responsible for plant cell death and for programmed cell death in humans. It develops its technologies for the commercial agriculture industry, including extending the shelf life of perishable plant products, producing larger and leafier crops, increasing crop yields, and reducing the harmful effects of environmental stresses, like drought. The company also engages in the development of technologies, which may address the various human diseases associated with suppressed or premature apoptosis, including cancer, glaucoma, and cardiovascular disease. It licenses its technology to agricultural companies. Senesco Technologies is based in New Brunswick, New Jersey.
IMMTECH INTERNATIONAL INC (IMM)
Immtech International, Inc., a pharmaceutical company, engages in the development and commercialization of oral drugs to treat infectious diseases, neoplastic cancer, and metabolic disorders. It also extends its proprietary aromatic cation technology platform to the treatment of cancer, diabetes, and other diseases. The company's development programs include treatments for malaria; fungal infections; tuberculosis; Pneumocystis pneumonia; and tropical diseases, including African sleeping sickness (trypanosomiasis). Immtech International is developing DB289 for treatment of African sleeping sickness, malaria, and Pneumocystis pneumonia. The company holds worldwide patent applications, licenses, and exclusive rights to commercialize products from a library of cationic compounds to develop a pipeline of products. Immtech was formed in 1984 and is based in Vernon Hills, Illinois.
NeoPharm, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cancer drugs for therapeutic applications in the United States. The company's drugs portfolio are based on two proprietary technology platforms, the NeoLipid liposomal drug delivery system, and a tumor-targeting toxin platform. Its products primarily include IL13-PE38QQR, a Phase III clinical trial product, which would be used for the treatment of glioblastoma multiforme, brain cancer; LE-SN38, a Phase I clinical trial product, for the treatment of colorectal cancer and other solid tumors; LEP-ETU, a Phase I clinical trial product, for the treatment of breast cancer, lung cancer, ovarian cancer, and other solid tumors; and LErafAON, a Phase I trail product, to be used for treating cancer. NeoPharm also develops NeoPhectin and NeoPhectin-AT, which are gene transfection kits. The company has a license agreement with Nippon Kayaku Co., Ltd., for the development and commercialization of IL13-PE38QQR in Japan. The company was incorporated in 1990 under the name OncoMed, Inc. and changed its name to NeoPharm, Inc. in 1995. NeoPharm is headquartered in Lake Forest, Illinois.
Antigenics, Inc., a biotechnology company, engages in the research and development of technology and products to treat cancers, infectious diseases, and autoimmune disorders. The company's principal product candidate, Oncophage, a personalized cancer vaccine, is in phase III clinical trials for the treatment of renal cell carcinoma and for metastatic melanoma, as well as in phase I/II trial for lung cancer. Its product portfolio also includes AG-858, a personalized cancer vaccine in a phase II clinical trial for the treatment of chronic myelogenous leukemia; AG-702/AG-707, a therapeutic vaccine program in phase I clinical development for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic for colorectal cancer and other solid tumors. The company was founded as Antigenics L.L.C. in 1994 and changed its name to Antigenics, Inc. in 2000. Antigenics is headquartered in New York City.
Curis, Inc., a therapeutic drug development company, focuses on the discovery and development of products that modulate key regulatory signaling pathways controlling the repair and regeneration of human tissues and organs. Its product development approach involves using small molecules, proteins, or antibodies to modulate these regulatory signaling pathways. Curis uses this product development approach to produce various drug product candidates in the fields of cancer, kidney disease, neurological disorders, hair growth, and cardiovascular disease. The company is developing its product candidate programs in various signaling pathways, including the Hedgehog and Bone Morphogenetic Protein pathways. Its lead product candidate is a topical therapy for the treatment of basal cell carcinoma and is under development in collaboration with Genentech, Inc. The company has strategic collaborations with Genentech and Wyeth Pharmaceuticals to develop therapeutics, which modulate the signaling of the Hedgehog pathway; an additional collaboration with Genentech to develop therapeutics that modulate an undisclosed signaling pathway that plays an important role in cell proliferation; and a research and development agreement with Procter & Gamble Pharmaceuticals U.K. Limited to evaluate and develop treatments for hair growth regulation utilizing Curis' Hedgehog agonist technology. Curis is headquartered in Cambridge, Massachusetts.
Inhibitex, Inc., a development stage company, engages in the discovery, development, and commercialization of antibody-based products for the prevention and treatment of bacterial and fungal infections in the hospital setting. The company has two products candidates in late stage clinical development, which include Veronate and Aurexis. Veronate, which is in phase III clinical development, is being developed to prevent hospital-associated infections in very low birth weight infants. Aurexis is being developed to treat, in combination with antibiotics, Staphylococcus aureus infections in hospitalized patients. Aurexis completed a phase II clinical trial in May 2005. In addition, the company has three preclinical product candidates under development, including Enterococcus monoclonal antibody for the treatment of enterococcus infections; Candida monoclonal antibody for the treatment of candida infections; and Staphylococcal vaccines for active immunity against Staphylococcal infections. Inhibitex was co-founded by Joseph M. Patti and Magnus Hook. It was incorporated in 1994 and is based in Alpharetta, Georgia.
No description available.
ACCENTIA BIOPHARMACEUTICALS INC (ABPI)
Accentia Biopharmaceuticals, Inc. engages in the development and commercialization of late-stage clinical products in the therapeutic areas of respiratory disease and oncology. The company operates through two segments, Biopharmaceuticals Products and Services, and Specialty Pharmaceuticals. The Biopharmaceuticals Products and Services segment develops late-stage biopharmaceutical products. Its products, which are under Phase III clinical trials, include SinuNase for chronic rhinosinusitis or chronic sinusitis, a long-term inflammatory condition of the paranasal sinuses; and BiovaxID, a patient-specific anticancer vaccine focusing on the treatment of follicular nonHodgkins lymphoma. This segment also engages in the analytical and consulting business, which provides various services relating to biopharmaceutical product development, as well as in the production of custom biologic products, and cell culture instruments and systems for biopharmaceutical and biotechnology companies, medical schools, universities, hospitals, and research institutions. The Specialty Pharmaceuticals segment markets and sells pharmaceutical products that are developed primarily by third-party development partners. Its specialty pharmaceuticals include Xodol, a narcotic pain formulation; Respi~TANN, a prescription antitussive decongestant for temporary relief of cough and nasal congestion; and a line of six HISTEX products for the cough, cold, and allergy prescription market. This segment also consists of pharmaceutical products under development, which include MD Turbo, a breath-actuated inhaler device used by patients with asthma and chronic obstructive pulmonary disease; Emezine, a transbuccal drug designed to control nausea and vomiting; and nine additional narcotic pain formulations for the treatment of moderate to moderately severe pain. The company was founded in 2002 and is based in Tampa, Florida.
CV THERAPEUTICS INC (CVTX)
CV Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of cardiovascular diseases. Its lead clinical development product includes Ranexa, which would be used for the treatment of chronic angina, a debilitating heart condition. The company also develops Regadenoson, a Phase III clinical trial product, an A2A-adenosine receptor agonist for use as a pharmacologic agent in cardiac perfusion imaging studies; Tecadenoson, a Phase III clinical trial product, an A1-adenosine receptor agonist for the reduction of rapid heart rate during atrial arrhythmias; and Adentri, a Phase II clinical trial product, an A1-adenosine receptor antagonist for the treatment of congestive heart failure. It also has various products in the pre-clinical stage development. It has collaboration agreement with Biogen, Inc. and Fujisawa Healthcare, Inc. In addition, the company is co-promoting ACEON tablets, an angiotensin converting enzyme inhibitor, with its collaborative partner, Solvay Pharmaceuticals, Inc. CV Therapeutics was founded in 1990 and is headquartered in Palo Alto, California.
MOMENTA PHARMACEUTICALS INC (MNTA)
Momenta Pharmaceuticals, Inc. engages in structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs, and the discovery of new biological processes. The company's products include M-Enoxaparin, a technology-enabled generic version of Lovenox and a low molecular weight heparin(LMWH), which is used to prevent and treat deep vein thrombosis and treat acute coronary syndromes; M-Dalteparin, also a technology-enabled generic version of the LMWH Fragmin. It also offers Glycoproteins, M118, pulmonary delivery of proteins, and sugar therapeutic, which are in preclinical stages. The company has collaboration agreements with Sandoz and Siegfried, Inc. and Siegfried, Ltd. The company was founded by Ganesh Venkataraman in 2001 as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in 2002. Momenta is based in Cambridge, Massachusetts.
ACORDA THERAPEUTICS INC (ACOR)
No description available.
CORCEPT THERAPEUTICS INCORPORATED (CORT)
Corcept Therapeutics Incorporated, a development stage biopharmaceutical company, engages in the development of drugs for the treatment of severe psychiatric and neurological diseases. The company develops CORLUX for the treatment of the psychotic features of psychotic major depression, which is in Phase III clinical trials. Corcept Therapeutics Incorporated was co-founded by Alan Schatzberg and Joseph K. Belanoff. The company was incorporated in 1998 and is based in Menlo Park, California.
TARGETED GENETICS CORPORATION (TGEN)
Targeted Genetics Corporation engages in the research and development of gene therapy products and technologies for treating both acquired and inherited diseases. Its product candidates include tgAAVCF, a phase II clinical trial product, for treating cystic fibrosis; tgAAC94, a Phase I clinical trial AAV-based product, for the treatment of rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis; and tgAAC09, a phase I clinical trial AAV-based prophylactic vaccine candidate, for high risk populations in developing nations to protect against the progression of Human Immunodeficiency Virus (HIV) and infection to Acquired Immune Deficiency Syndrome (AIDS). The company also engages in exploring gene therapies for cardiovascular disease by applying its AAV vector technology to treating hyperlipidemia, the elevation of lipids, or fats, such as cholesterol in the bloodstream. Targeted Genetics was incorporated in 1989 and is based in Seattle, Washington.
CRITICAL THERAPEUTICS INC (CRTX)
Critical Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of products to treat respiratory, inflammatory, and critical care diseases. The company's primary product is Zyflo Filmtab, a tablet formulation of zileuton for the prevention and chronic treatment of asthma. Its products under development include Zileuton, through development of additional formulations, controlled-release formulation and an intravenous formulation; CTI-01, a small molecule product candidate for patients who are at high risk for post-surgical complications following cardiopulmonary bypass; HMGB1, a cytokine, for the development of products to treat inflammation-mediated diseases; and Alpha-7, a small molecules designed to inhibit the body's inflammatory response by acting on the nicotinic alpha-7 cholinergic target. Critical Therapeutics has strategic collaboration with MedImmune, Inc. and Beckman Coulter, Inc. The company was co-founded by Mitchell Fink, Kevin Tracey, and H. Shaw Warren. Critical Therapeutics was incorporated in 2000 as Medicept, Inc. and changed its name to Critical Therapeutics, Inc. in 2001. The company is headquartered in Lexington, Massachusetts.
XTL BIOPHARMACEUTICALS LTD (XTLB)
No description available.